ZA200202577B - Modified peptides and peptidomimetics for use in immonotherapy. - Google Patents
Modified peptides and peptidomimetics for use in immonotherapy. Download PDFInfo
- Publication number
- ZA200202577B ZA200202577B ZA200202577A ZA200202577A ZA200202577B ZA 200202577 B ZA200202577 B ZA 200202577B ZA 200202577 A ZA200202577 A ZA 200202577A ZA 200202577 A ZA200202577 A ZA 200202577A ZA 200202577 B ZA200202577 B ZA 200202577B
- Authority
- ZA
- South Africa
- Prior art keywords
- ser
- gly
- thr
- ala
- phe
- Prior art date
Links
- 108091005601 modified peptides Proteins 0.000 title claims description 30
- 239000000816 peptidomimetic Substances 0.000 title description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 171
- 229940024606 amino acid Drugs 0.000 claims description 71
- 125000000217 alkyl group Chemical group 0.000 claims description 64
- 150000001413 amino acids Chemical class 0.000 claims description 60
- -1 1-methyl-pyridinium-3- carbonyl Chemical group 0.000 claims description 45
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 43
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 42
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 42
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 32
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 29
- 125000003118 aryl group Chemical group 0.000 claims description 26
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 24
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 21
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 16
- AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 claims description 15
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 15
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 230000004048 modification Effects 0.000 claims description 12
- 238000012986 modification Methods 0.000 claims description 12
- 208000023275 Autoimmune disease Diseases 0.000 claims description 11
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 11
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims description 10
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 10
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 238000006467 substitution reaction Methods 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 9
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims description 8
- 229940124280 l-arginine Drugs 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 7
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 6
- 210000004899 c-terminal region Anatomy 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 4
- 239000005977 Ethylene Substances 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 claims description 4
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 230000006698 induction Effects 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- SNDPXSYFESPGGJ-SCSAIBSYSA-N D-2-aminopentanoic acid Chemical compound CCC[C@@H](N)C(O)=O SNDPXSYFESPGGJ-SCSAIBSYSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 3
- JPZXHKDZASGCLU-GFCCVEGCSA-N 3-(2-Naphthyl)-D-Alanine Chemical compound C1=CC=CC2=CC(C[C@@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-GFCCVEGCSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 2
- 125000003558 D-valino group Chemical group C(=O)(O)[C@@H](C(C)C)N* 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 241000663636 Alternaria allii Species 0.000 claims 1
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims 1
- PQBAWAQIRZIWIV-UHFFFAOYSA-N N-methylpyridinium Chemical compound C[N+]1=CC=CC=C1 PQBAWAQIRZIWIV-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 60
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 46
- 239000000427 antigen Substances 0.000 description 39
- 108091007433 antigens Proteins 0.000 description 39
- 102000036639 antigens Human genes 0.000 description 39
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 32
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 28
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 25
- 238000004128 high performance liquid chromatography Methods 0.000 description 25
- 125000004432 carbon atom Chemical group C* 0.000 description 21
- 239000011347 resin Substances 0.000 description 21
- 229920005989 resin Polymers 0.000 description 21
- 210000004408 hybridoma Anatomy 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 229920000361 Poly(styrene)-block-poly(ethylene glycol) Polymers 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 16
- 206010039073 rheumatoid arthritis Diseases 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 15
- 238000004255 ion exchange chromatography Methods 0.000 description 14
- 230000008878 coupling Effects 0.000 description 13
- 238000010168 coupling process Methods 0.000 description 13
- 238000005859 coupling reaction Methods 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 12
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 239000007821 HATU Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 230000000638 stimulation Effects 0.000 description 11
- 238000010626 work up procedure Methods 0.000 description 11
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 10
- 229910019142 PO4 Inorganic materials 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 235000021317 phosphate Nutrition 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 8
- 239000010452 phosphate Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 7
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 238000011033 desalting Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 230000009696 proliferative response Effects 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 5
- 108010043958 Peptoids Proteins 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 210000000845 cartilage Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 230000024664 tolerance induction Effects 0.000 description 5
- YBADLXQNJCMBKR-UHFFFAOYSA-N (4-nitrophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C([N+]([O-])=O)C=C1 YBADLXQNJCMBKR-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 229910004373 HOAc Inorganic materials 0.000 description 4
- 102000043131 MHC class II family Human genes 0.000 description 4
- 108091054438 MHC class II family Proteins 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000001270 agonistic effect Effects 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 229960004132 diethyl ether Drugs 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 229960003767 alanine Drugs 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 150000001408 amides Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 2
- FOUZISDNESEYLX-UHFFFAOYSA-N 2-(2-hydroxyethylazaniumyl)acetate Chemical compound OCCNCC(O)=O FOUZISDNESEYLX-UHFFFAOYSA-N 0.000 description 2
- ATYUCXIJDKHOPX-UHFFFAOYSA-N 5-[4-[(9h-fluoren-9-ylmethoxycarbonylamino)methyl]-3,5-dimethoxyphenoxy]pentanoic acid Chemical compound COC1=CC(OCCCCC(O)=O)=CC(OC)=C1CNC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ATYUCXIJDKHOPX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000018704 Chitinase-3-Like Protein 1 Human genes 0.000 description 2
- 108010066813 Chitinase-3-Like Protein 1 Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108010029657 HLA-DRB1*04:01 antigen Proteins 0.000 description 2
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101710176384 Peptide 1 Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000006472 autoimmune response Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 150000003857 carboxamides Chemical group 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000011191 terminal modification Methods 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 1
- HEPOIJKOXBKKNJ-UHFFFAOYSA-N 2-(propan-2-ylazaniumyl)acetate Chemical compound CC(C)NCC(O)=O HEPOIJKOXBKKNJ-UHFFFAOYSA-N 0.000 description 1
- BLMLZYILSIZQTL-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxy]ethanamine Chemical compound CC(C)(C)OCCN BLMLZYILSIZQTL-UHFFFAOYSA-N 0.000 description 1
- MUSGYEMSJUFFHT-UWABRSFTSA-N 2-[(4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-[[(2S,3S)-2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]-methylcarbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13,17-dimethyl-28-[(1-methylindol-3-yl)methyl]-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](N)Cc1ccc(O)cc1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](C)NC(=O)CN(C)C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cn(C)c3ccccc23)NC(=O)[C@@H](NC1=O)C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)C(N)=O MUSGYEMSJUFFHT-UWABRSFTSA-N 0.000 description 1
- YDBPFLZECVWPSH-UHFFFAOYSA-N 2-[3-(diaminomethylideneamino)propylamino]acetic acid Chemical compound NC(=N)NCCCNCC(O)=O YDBPFLZECVWPSH-UHFFFAOYSA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- CGWYFJCXGHFUBB-UHFFFAOYSA-N 2-amino-7-(9h-fluoren-9-ylmethoxy)-7-oxoheptanoic acid Chemical compound C1=CC=C2C(COC(=O)CCCCC(N)C(O)=O)C3=CC=CC=C3C2=C1 CGWYFJCXGHFUBB-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-UHFFFAOYSA-N 2-aminohexanoic acid Chemical compound CCCCC(N)C(O)=O LRQKBLKVPFOOQJ-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 102100025142 Beta-microseminoprotein Human genes 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229930195711 D-Serine Natural products 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 101000759376 Escherichia phage Mu Tail sheath protein Proteins 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000576812 Homo sapiens Beta-microseminoprotein Proteins 0.000 description 1
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 1
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 1
- 101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 description 1
- 101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 description 1
- 101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101001043827 Mus musculus Interleukin-2 Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- 229910020889 NaBH3 Inorganic materials 0.000 description 1
- IDGQXGPQOGUGIX-VIFPVBQESA-N O-BENZYL-l-SERINE Chemical compound OC(=O)[C@@H](N)COCC1=CC=CC=C1 IDGQXGPQOGUGIX-VIFPVBQESA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 101150010457 SAS5 gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- 235000001468 Triticum dicoccon Nutrition 0.000 description 1
- 240000000359 Triticum dicoccon Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
- 239000012345 acetylating agent Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940001007 aluminium phosphate Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000000599 auto-anti-genic effect Effects 0.000 description 1
- 230000006470 autoimmune attack Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- UKUBCVAQGIZRHL-UHFFFAOYSA-N delta-Guanidinovaleric acid Chemical compound NC(N)=NCCCCC(O)=O UKUBCVAQGIZRHL-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000054350 human CHI3L1 Human genes 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- YRCHYHRCBXNYNU-UHFFFAOYSA-N n-[[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-(4-fluorophenyl)acetamide Chemical compound N1=CC(CNCCOC)=CC=C1C1=CC2=NC=CC(OC=3C(=CC(NC(=S)NC(=O)CC=4C=CC(F)=CC=4)=CC=3)F)=C2S1 YRCHYHRCBXNYNU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 238000006578 reductive coupling reaction Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 101150007503 rps1 gene Proteins 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rehabilitation Therapy (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Modified peptides and peptidomimetics for use in immunotherapy
The present invention relates to modified peptides which are based on HC gp-39 (263- 275), pharmaceutical compositions comprising such peptides as well as the use of these peptides for inducing tolerance induction in patients suffering from autoimmune diseases.
The immune system is established on a principle of discrimination between foreign antigens (non-self antigens) and autoantigens (self antigens, derived from the individuals own body) achieved by a build-in tolerance against the autoantigens. io The immune system protects individuals against foreign antigens and responds to exposure to a foreign antigen by activating specific cells such as T- and B lymphocytes and producing soluble factors like interleukins, antibodies and complement factors. The antigen to which the immune system responds is degraded by the antigen presenting cells (APCs) and a fragment of the antigen is expressed on the cell surface associated with a major histocompatibility complex (MHC) class II glycoprotein. The MHC- ‘ glycoprotein-antigen-fragment complex is presented to a T cell which by virtue of its T cell receptor recognizes the antigen fragment conjointly with the MHC class II protein to which it is bound. The T cell becomes activated, i.e. proliferates and/or produces interleukins, resulting in the expansion of the activated lymphocytes directed to the antigen under attack (Grey et al., Sci. Am., 261:38-46. 1989).
Self antigens are also continuously processed and presented as antigen fragments by the
MHC glycoproteins to T cells (Jardetsky et al., Nature 353:326-329, 1991). Self recognition thus is intrinsic to the immune system. Under normal circumstances the immune system is tolerant to self antigens and activation of the immune response by these self antigens is avoided.
When tolerance to self antigens is lost, the immune system becomes activated against one or more self antigens, resulting in the activation of autoreactive T cells and the production of autoantibodies. This phenomenon is referred to as autoimmunity. As the immune response in general is destructive, i.e. meant to destroy the invasive foreign antigen, autoimmune responses can cause destruction of the body's own tissue.
The contribution of T cells to autoimmune diseases has been established in several studies. In mice, experimental autoimmune encephalomyelitis (EAE) is mediated by a highly restricted group of T cells, linked by their specificity for a single epitope of myelin basic protein (MBP) complexed to an MHC class II molecule. In the Lewis rat, 5s a species with high susceptibility to various autoimmune diseases, disease has been shown to be mediated by T cells. In humans autoimmune diseases are also thought to be associated with the development of auto-aggressive T cells.
A destructive autoimmune response has been implicated in various diseases such as rheumatoid arthritis (RA), in which the integrity of articular cartilage is destroyed by a chronic inflammatory process resulting from the presence of large numbers of activated lymphocytes and MHC class II expressing cells. The mere presence of cartilage appears necessary for sustaining the local inflammatory response: it has been suggested that cartilage degradation is associated with the activity of cartilage-responsive autoreactive
T cells in RA (Sigall et al., Clin. Exp. Rheumat. 6:59, 1988; Glant et al., Biochem. Soc.
Trans. 18:796, 1990; Burmester et al., Rheumatoid arthritis Smolen, Kalden, Maini (Eds) Springer-Verlag Berlin Heidelberg, 1992). Furthermore, removal of cartilage from RA patients by surgery was shown to reduce the inflammatory process (R.S.
Laskin, J. Bone Joint Surgery (Am) 72:529, 1990). The cartilage proteins are therefore : 20 considered to be target autoantigens which are competent of stimulating T cells.
Activation of these autoreactive T cells leads to development of autoimmune disease.
However, the identification of the autoantigenic components that play a role in the onset of rheumatoid arthritis has so far remained elusive.
The inflammatory response resulting in the destruction of the cartilage can be treated by several drugs, such as for example steroid drugs. However, these drugs are often immunosuppressive drugs that are nonspecific and have toxic side effects. The disadvantages of nonspecific immunosuppression makes this a highly unfavourable therapy.
The antigen-specific, nontoxic immunosuppression therapy provides a very attractive alternative for the nonspecific immunosuppression. This antigen-specific therapy involves the treatment of patients with the target autoantigen or with synthetic T cell- reactive peptides derived from the target autoantigen. These synthetic peptides correspond to T cell epitopes of the autoantigen and can be used to induce specific T cell tolerance both to themselves and to the autoantigen. Desensitization or immunological tolerance of the immune system is based on the long-observed phenomenon that animals which have been fed or have inhaled an antigen or epitope are less capable of developing a systemic immune response towards said antigen or epitope when said antigen or epitope is introduced via a systemic route.
Rheumatoid arthritis is an autoimmune disease that occurs more frequently in HLA-
DR4-positive individuals. The disease association may indicate that DR4 molecules present autoantigens to T-cells. The target of this autoimmune disease is the joint where the articular chondrocyte presents a unique cell type producing products organized in a matrix. It is thought that joint destruction as seen in RA is mediated by cartilage-specific, autoreactive T-cells. The cartilage-denved protein Human Cartilage gp-39 (HC gp-39) has recently been identified as a candidate autoantigen in RA. A dominant epitope of the HC gp-39 protein, the peptide covering the 263-275 sequence, was preferentially recognized in RA patients suggesting that this epitope is a target of the autoimmune attack in rheumatoid arthritis. Eight out of 18 RA patients responded : to this peptide and no responders were found in the healthy donor group (Verheijden et al., Arthtritis Rheum. 40:1115, 1997). Thus, the data strongly suggest that this peptide . or the HC gp-39 protein is a target for immune recognition in the joint.
The significance of HC gp-39 for arthritic disease was further demonstrated by its arthritogenicity in Balb/c mice. A single injection in the chest region with pug amounts of protein mixed in IFA, induced a chronic joint inflammation reminiscent of RA.
The response to the HC gp-39 peptide 263-275 was further examined by generating a set of DRB1*0401-restricted, peptide-specific T-T hybridomas from DRB1*0401- transgenic mice following immunisation with HC gp-39. The fine specificity of the hybridomas specific for peptide 263-275 in the context of DR4 (DB1*0401) was defined and compared. As a result 3 hybridomas differing in their recognition of the 263-275 epitope presented by DRB1*0401 encoded molecules were identified. (The difference in epitope recognition between the three hybridomas used became visible when N- and C-terminal truncated peptides within the 263-275 sequence were used for stimulation of the different hybridomas). The 5G11 hybridoma was found to respond optimally to the 265-275 sequence. In contrast, recognition by the 8B12 hybridoma was centered around sequence 264-274 whereas the 14G11 hybridoma was optimally responsive to 264-275.
Tolerization of HC gp-39 (263-275)-reactive T-cells may be of benefit to RA patients.
The present invention provides for modified peptide derivatives based on the HC gp-39 (263-275) sequence which are superior in their capacity to induce an immune response and in their tolerizing capacity.
It was surprisingly found that specific peptide modifications based on HC gp-39 (263- 275) are agonistic for a set of T-cell hybridomas specific for HC gp-39 (263-275) peptide and superior in stimulation of two human T-cell clones generated following stimulation with peptides accommodating the 263-275 epitope sequence. Moreover, these modified peptides showed a superior tolerizing capacity in vivo.
Thus according to one aspect of the invention there is provided a modified peptide derived from H-Arg-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-OH (formula
I; SEQ ID NO:1) having general formula Q- A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-
All1-Al2-A13- Z (formula II). In general formula II, Al through A13 correspond with the amino acids of formula I, Q corresponds with H and Z corresponds with OH. The modifications according to the present invention are selected from the group consisting of a) substitution of 1-6, preferably 1-4 amino acids at Al through A13 with non-natural amino acids or 3 amino acids b) substitution of one or more amide bonds with reduced amide bonds or ethylene isosteres c) substitutions at Q and/or Z.
The number of modifications to be selected from one or more of these groups amounts 1-6. In addition the amino acids may be substituted with other natural amino acids provided that the total number of modifications does not exceed the number of 6.
Modified peptides based on formula I (HC gp-39 (263-275)) may be stabilised by C- and/or N- terminal modifications, which will decrease exopeptidase catalysed hydrolysis. Such modifications may include N-terminal acylation, (e.g. acetylation =
Ac-peptide), C-terminal amide introduction, (e.g. peptide-NH,), combinations of acylation and amide introduction (e.g. Ac-peptide-NH,) and e.g. introduction of D-
amino acids instead of L-amino acids. Other modifications are focused on the prevention of hydrolysis by endopeptidases.
Table 1. Peptide linkages
EE EE
Structure Name -YYY——-——_--——— 1 . bi Peptide
H oo Rr 0
Ri Ry Reduced peptide
ANA
H R, H
Ry 0 Vinylogous peptides
H
“N A A Ay
H 0} Ra 0 .
Pe Peptoid -
Ry O Rs ©O
Ry HO ORs N-hydroxy-peptide :
AAA
H t
OH 0} R, OH o
Ry hig Eo H Oligocarbamates
H H fo) O bi Tox H Oligourea wow
HH 0 R 2
Re H Ra H Re Hydrazinopeptides
HaNC : ~ ~ FN
NN
Ry ©O Ry ©O Rs
R2 0.0 Oligosulphone
Sg NS
H n~0 =
Ry 0 Rj
Q oR 90 R2 Peptidosulphonamides
H H
NP Ethylene isostere p
Examples of these modifications are introduction of D-amino acids instead of L-amino acids, modified amino acids, cyclisation within the peptide, introduction of modified peptide bonds, e.g. reduced peptide bonds y[CH,NH] and peptoids (N-alkylated glycine derivatives).
Other peptide analogues may be related to the peptides of formula I or general formula
II but instead of the conventional -NH-C(O)- peptide bonds, the linkages shown in
Table 1, or any combination thereof may be used instead of the individual -NH-C(O)- bonds. If the amino group at the N-terminus has been removed (e.g. Al = desaminoarginine in formula IT) Q in formula II corresponds to no atom. } Preferred peptides according to the invention are peptides wherein Q is H, (C.)alkyl, formyl, (C,.¢)alkylcarbonyl, carboxy(C,.¢)alkyl, (C,.¢)alkyloxycarbonyl, (C,. : ¢)alkenyloxycarbonyl, (Ce.14)aryl(Cy.¢)alkyl; (Cs.14)aryl(C;.4)alkyloxycarbonyl,
CH;3(OCH,CH,),-OCH,-C(O)- wherein n is 1-10, HOCH,-(CHOH)n,-CH;- whercin m is 3-4; 1-methyl-pyridinium-3-carbonyl, 1-methyl-pyridinium-4-carbonyl or Lys or Q is absent if Al is H,N-C(=NH)NH-(CH,),-C(O)-wherein n is 2-5;
Z is OR wherein R is H, (C,.¢)alkyl, (Ca.¢)alkenyl, (Cq.14)aryl(C 4)alkyl, (Ce-14)(Cas- 13)heteroaryl(C,6)alkyl or NR|R; wherein R} and R; are independently selected from H, (Ci-s)alkyl or (Ce.14)aryl(C,.s)alkyl; and, optionally, Q and Z contain in addition together up to 10 amino acids located next to position Al and/or A13. Substitution at Al through A13 with one or more other natural amino acids preferably is performed at no more than four, more preferably two positions.
In the peptides according to the present invention the following substitutions at general formula II are to be preferred:
Q is H, (C,.)alkyl, formyl, (C,.¢)alkylcarbonyl, carboxy(C,.¢)alkyl, (C.¢)alkyloxy- carbonyl, (C,.¢)alkenyloxycarbonyl, (Ce-14)aryl(Ci.¢)alkyl; (Cs.14)aryl(C,. a)alkyloxycarbonyl, CH3(OCH,CH,),-OCH,-C(O)- wherein n is 1-10, HOCH,-
. (CHOH)n-CHz- wherein m is 3-4; 1-methyl-pyridinium-3-carbonyl, I-methyl- pyridinium-4-carbonyl or Lys, or Q is absent if Al is HN-C(=NH)NH-(CH,),-C(O)- wherein n is 2-5. More preferred are substitions wherein Q is H, (C;.¢)alkyl, (C,. s)alkylcarbonyl, carboxy(C,.¢)alkyl, (C,.¢)alkyloxycarbonyl, CH3(OCH;CH,),-OCH,-
C(O)- wherein n is 1-10, HOCH,-(CHOH),-CH,- wherein m is 3-4; 1-methyl- pyridinium-3-carbonyl, 1-methyl-pyridinium-4-carbonyl or Lys, or Q is absent if Al is
H,N-C(=NH)NH-(CH;),-C(O)-wherein n is 2-5. Even more preferred are peptides wherein is Q is H, methyl; acetyl; carboxymethylene, methoxycarbonyl;
CH;(OCH;,CH,)3-OCH,-C(0O)-, D-1-glucityl, 1-methyl-pyridinium-3-carbonyl or 1- methyl-pyridinium-4-carbonyl, or Q is absent if Al is HoN-C(=NH)NH-(CH,)s-C(O)-.
Al is L-Arg, D-Arg, L-Lys, D-Lys, L-Ala, D-Ala, HoN-C(=NH)NH-(CH,),-C(O)- wherein n is 2-5, HyN-(CH;),-C(O)-, wherein n is 2-7, (R)-{-NH-CH[(CH,),-NH-
C(=NH)-NH;}-CH,-C(O)-}, wherein n is 2-5 or (§)-{-NH-CH[(CH,),-NH-C(=NH)-
NH,]-CH,-C(0)-}, wherein n is 2-5 or -N[(CHz),-NH-C(=NH)-NH;]CH,C(O)-, : 15 wherein nis 2-5. Preferably Al is L-Arg, D-Arg, L-Ala, H,N-C(=NH)NH-(CH3),- }
C(O)-wherein n is 2-5, H;N-(CH3),-C(O)-, wherein n is 2-7, (S)-{-NH-CH[(CH;),-NH-
C(=NH)-NH,]-CH,-C(0)-}, wherein n is 2-5 or -N[(CH2),-NH-C(=NH)-
NH,]CH,C(O)-, wherein n is 2-5. More preferably Al is L-Arg, D-Arg, L-Ala, H,N-
C(=NH)NH-(CH,)4-C(O)-, H,N-(CH;),-C(O)-, wherein n is 5-7, (S)-{-NH-CH[(CH,)3-
NH-C(=NH)-NH;]-CH,-C(0)-} or -N[(CH_);-NH-C(=NH)-NH;]CH,C(O)-.
A2 is L-Ser, D-Ser, L-hSer, D-hSer, L-Thr, D-Thr, L-Ala, D-Ala, Gly or -N[(CH3),-
OH]-CH,-C(O)- wherein n is 2-5. Preferably A2 is L-Ser, L-Ala, D-Ala, Gly or -
N[(CH;),-OH]-CH,-C(O)- wherein n is 2-5. More preferably A2 is L-Ser, L-Ala or -
N[(CH,);-OH}-CH,-C(O)-.
A3 is L-Phe, D-Phe, L-Phe(X), D-Phe(X) wherein X is independently selected from one or more of (C,4)alkyl, hydroxy, halo, (Cj.¢)alkylcarbonylamino, amino or nitro, L-
Hfe, D-Hfe, L-Thi, D-Thi, L-Cha, D-Cha, L-Pal(3), D-Pal(3), L-1-Nal, D-1-Nal, L-2-
Nal, D-2-Nal, L-Ser(Bzl), D-Ser(Bzl), (R)-{-NH-CH(CH;-aryl)-CH»-} or (S)-{-NH-
CH(CH;-aryl)-CH,-} or (R)-{-NH-CH(CH;-aryl)-CH>-} or (S)-{-NH-CH(CH,-aryl)-
CHo,-}. Preferably A3 is L-Phe, D-Phe, L-Phe(X) or D-Phe(X) wherein X is halo or nitro, L-Hfe, L-Thi, L-Cha, L-Pal(3), L-1-Nal, L-2-Nal, L-Ser(Bzl) or (S)-{-NH-
CH(CHz;-aryl)-CH,-}. More preferably A3 is L-Phe. D-Phe, L-Phe(X) wherein X is halo or nitro, L-Hfe, L-Thi, L-Cha. L-Pal(3), L-1-Nal. L-2-Nal or L-Ser(Bzl).
A4 is L-Thr, D-Thr- L-Ser-, D-Ser. L-hSer. D-hSer, L-Ala, D-Ala or Gly. Preferably
Ad is L-Thr or L-Ala.
A5isL-Leu, D-Leu, L-Ile, D-lle, L-Val, D-Val-, L-Nva, D-Nva, L-Ala, D-Ala, Gly, (R)-{-NH-CH(CH,-CH(CH3;),)-CH;-}, or (S)-{-NH-CH(CH,-CH(CHs;),)-CH;-}.
Preferably AS is L-Leu, L-Ala, or (S)-{-NH-CH(CH,-CH(CH3);)-CH,-}.
A6 is L-Ala, D-Ala or Gly. Preferably A6 is L-Ala or Gly.
A7 is L-Ser, D-Ser, L-hSer, D-hSer, L-Thr, D-Thr, L-Ala, D-Ala or Gly. Preferably A7 is L-Seror L-Ala.
A8 is L-Ser, D-Ser, L-hSer, D-hSer, L-Thr, D-Thr, L-Ala, D-Ala or Gly. Preferably A$ is L-Ser or L-Ala. } A9 is L-Glu, D-Glu, L-Asp, D-Asp, L-Ala, D-Ala or Gly. Preferably A9 is L-Glu or L-
Ala. } 15 AlO is L-Thr, D-Thr, L-Ser, D-Ser, L-hSer, D-hSer, L-Ala, D-Ala or Gly. Preferably
A10 is L-Thr or L-Ala.
All is Gly, L-Ala, D-Ala or -NH-CH;-CH;-. Preferably A11 is Gly, L-Ala or -NH-
CH,-CH,-.
Al2is L-Val, D-Val, L-Nva, D-Nva, L-Leu, D-Leu, L-Ile, D-Ile, (R)-{-NH-
CH[CH(CH3),]-CHs-}, (S)-{-NH-CH[CH(CH3),]-CH;-}, (R)-{-NH-
CH[CH,CH,CHj;]-CH;-}, (S§)-{-NH-CH[CH,CH,CH;]-CH;-}, (R)-{-NH-
CH[CH,CH(CHz;).]-CH,-}, (S§)-{-NH-CH[CH,CH(CH3;),]-CH,-}, (RR)-{-NH-
CH[CH(CH(CH3)-CH,CH3]-CH;-}, (RS)-{-NH-CH[CH(CH(CHj3)-CH,CH;]-CH;-}, (SR)-{-NH-CH[CH(CH(CH3)-CH,CH3]-CH;-, or (5S)-{-NH-CH[CH,(CH(CH3)-
CH;CH3]-CHy-}. Preferably A12 is L-Val or (S)-{-NH-CH[CH(CHj3),]-CH,-}.
A13 is Gly, L-Ala or D-Ala. Preferably A13 is Gly or L-Ala
Furthermore, in the peptides according to the invention Z is OR wherein R is H, (C;. e)alkyl, (Cs.¢)alkenyl, (Ce.14)aryl(Ci4)alkyl, (Cq.13)heteroaryl(C,.¢)alkyl or NR|R; wherein R; and R; are independently selected from H, (Cy.¢)alkyl or (Cq.14)aryl(C). alkyl. Preferably Z is OR wherein R is H or NR R; wherein R, and R; are independently selected from H or (C,¢)alkyl. More preferably Z is OH, NH, or NHE.
The peptides according to the invention optionally may be extended at the N and C terminal end. i.e. next to Al and /or A13 with several amino acids. Preferably they may be extended with up to 10 amino acids. Thus, Q and Z may contain in addition together : up to 10 amino acids located next to position Al and/or A13.
The peptides may differ from general formula I at several positions but preferably they are modified at 1-4 positions, more preferably at 2-3 positions.
As used herein the term (C,.¢)alkyl means a branched or unbranched alkyl group having 1-6 carbon atoms, for example methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert- butyl and hexyl. Most preferred are alkyl groups having 1-4 carbon atoms.
The term (C,4)alkyl means a branched or unbranched alkyl group having 1-4 carbon : atoms.
The term (Cj.)alkenyl means a branched or unbranched alkenyl group having 2-6 : carbon atoms, such as ethenyl, 2-butenyl etc. (C,4)Alkenyl groups are preferred, (C,. 3)alkenyl groups being the most preferred. ‘The term (C,.)alkylcarbonyl means a branched or unbranched alkyl group having 1-6 carbon atoms, attached to a carbonyl group, for example an acetyl group. Most preferred are alkyl groups having 1-4 carbon atoms.
The term carboxy-(C;¢)alkyl means a carboxy group attached to a branched or unbranched alkyl group having 1-6 carbon atoms. Most preferred are alkyl groups having 1-4 carbon atoms.
The term (C,)alkyloxycarbonyl means a branched or unbranched alkyl group, attached to an oxycarbonyl group, for example a methoxycarbonyl-, or a tert-butyloxycarbonyl- (Boc-) group. Most preferred are alkyl groups having 1-4 carbon atoms.
The term (C,.¢)alkenyloxycarbonyl means a branched or unbranched alkenyl group having 2-6 carbon atoms as defined previously, attached to an oxycarbonyl group, for example an allyloxycarbonyl group. (C4)Alkenyl groups are preferred, (C,.3)alkenyl groups being the most preferred.
The term (C,.s)(di)alkylamino means a (di)alkylamino group having 1-6 carbon atoms, the alkyl moiety having the same meaning as previously defined. Preferred are alkyl groups having 1-4 carbon atoms.
The term amino(C,.¢)acyl means an acyl group having 1-6 carbon atoms, functionalized with an amino group. Preferred are acyl groups having 1-4 carbon atoms.
The term (Ce.14)aryl means an aromatic hydrocarbon group having 6-14 carbon atoms, such as phenyl, naphthyl. tetrahvdronaphthyl, indenyl. anthracyl, which may optionally be substituted at the ortho and/or meta position with one or more substituents such as - but not limited to- hydroxy, halogen, nitro, cyano, amino((Cj.¢)acyl) or (di)(C,. s)alkylamino. the acyl and alkyl moiety having the same meaning as previously defined. (Cé-10)Aryl groups are preferred. phenyl being the most preferred.
The term (Ca.j3)heteroaryl(C;¢)alkyl means a substituted or unsubstituted aromatic group having 4-13 carbon atoms, preferably 4-9, at least including one heteroatom selected from N, O and/or S, connected to a branched or an unbranched alkyl group having 1-6 carbon atoms. The substituents on the heteroaryl group may be selected from the group of substituents listed for the aryl group. Nitrogen-containing heteroaryl groups may either be connected via a carbon or a nitrogen atom to the alkyl group. Of the alkyl groups, groups having 1-4 carbon atoms are preferred.
The term (C,.¢)alkyl(Cs.14)aryl means means a branched or unbranched alkyl group as defined previously, attached to an aryl group as defined previously. (Ce.10)Aryl groups are preferred, phenyl being the most preferred. Of the alkyl groups, groups having 1-4 carbon atoms are preferred.
The term (Ce.14)aryl(Ci.¢)alkyl means an arylalkyl group, wherein the alkyl group is a (Cys)alkyl group and the aryl group is a (Ce.14)aryl as defined previously, for example a benzyl- (Bzl) or a triphenylmethyl- (Trt) group. (Ce.10)Aryl groups are preferred, phenyl being the most preferred. Of the alkyl groups, groups having 1-4 carbon atoms are preferred.
The term (C,.s)alkylcarbonylamino means an alkylcarbonylamino group, the alkyl group of which contains 1-6 carbon atoms and has the same meaning as previously defined. Alkyl groups having 1-4 carbon atoms are preferred.
The term (Cs.14)aryl(C;4)alkyloxycarbonyl means an (Cg. 14)aryl group connected to an alkyloxycarbonyl group, wherin the alkyl group is a (Cj4)alkyl group, and the aryl group is defined as previously, for example a benzyloxycarbonyl- (Z) or an Fluorenyl- methoxycarbonyl- (Fmoc) group. (Cs.10)Aryl groups are preferred, phenyl being the most preferred.
The term halo means F, Cl, Bror I.
The naturally occurring amino acids are shown using their abbreviations (3-letter code) as follows: alanine (Ala), arginine (Arg), asparagine (Asn), aspartic acid (Asp), cysteine (Cys), glutamine (Gln), glutamic acid (Glu), glycine (Gly), histidine (His), serine (Ser), isoleucine (lle), leucine (Leu), lysine (Lys), methionine (Met), phenylalanine (Phe), proline (Pro), threonine (Thr), tryptophan (Trp), tyrosine (Tyr) and valine (Val). Of all = the amino acids the stereochemistry is defined as L-.
A non-natural amino acid is an, optionally Na-substituted, a-amino acid having a chemical structure not identical to those of the natural amino acids. Non-natural amino acids are e.g. Phe(X), with X is a substituent situated at the para position of the phenyl ring of Phe, hSer (2-amino-4-hydroxybutanoic acid), norleucine (Nle, 2-aminohexanoic acid), norvaline (Nva, 2-ammopentanoic acid), L-Hfe (L-a-homophenylalanine), D-Hfe (D-a-homophenylalanine), L-Thi (B-thienyl-L-alanine), D-Thi (f-thienyl-D-alanine),
L-Cha (B-cyclohexyl-L-alanine), D-Cha (B-cyclohexyl-D-alanine), L-Pal(3) (B-3- pyridyl-L-alanine), D-Pal(3) (p-3-pyridyl-D-alanine), L-1-Nal (f-1-naphthyl-L- 1s alanine), D-1-Nal (B-1-naphthyl-D-alanine), L-2-Nal (B-2-naphthyl-L-alanine), D-2-
Nal (B-2-naphthyl-D-alanine), L-Ser(Bzl) (O-benzyl-L-serine), D-Ser(Bzl) (O-benzyl- a D-serine) and N-alkylglycine derivatives such as NVal (N-isopropylglycine, NArg (N- (3-guanidinopropyl)glycine) and NhSer (N-(2-hydroxyethyl)glycine). Included within this group of amino acids are also the naturally occurring amino acids, the stereochemistry of which is defined as D-.
It is to be understood that in a peptide incorporating a reduced amide bond the original carbonyl group of the amino acid has been replaced by a methylene group. In a peptide incorporating an ethylene isostere the original carboxamide function (-C(O)-NR-) has been replaced by an ethylene group (-CH=CR-).
The term y[CH,NH] between two amino acid residues in a sequence means that the original amide bond (-C(O)-NH-) between those amino acid residues has been replaced by a reduced amide bond (-CH,NH-).
Several amino acids as indicated in formula I are preferred to be fixed at the corresponding positions at general formula 2. Thus, a preferred embodiment of the invention is a modified peptide having general formula Q-A1-A2-A3-Thr-Leu-Ala-Ser-
Ser-Glu-Thr-A11-A12-Gly-Z (formula III) wherein Q, Al, A2, A3, All, A12 and Z are as defined previously. The most preferred substitutions in general formula III are for
Al
L-Arg, D-Arg, H,N-C(=NH)NH-(CH,)4-C(O)-, H;N-(CH;),-C(O)-, wherein n is 5-7 or -N[(CH;)3;-NH-C(=NH)-NH,]CH,C(O)-. for A2 L-Ser or -N{(CH,),-OH]-CH,-C(O)- ,and for A3 L-Phe, L-Phe(X) wherein X is halo, L-1-Nal, L-2-Nal, L-Ser(Bzl), L-Thi,
L-Cha or L-Pal(3). s More preferred are peptides according to general formula III wherein Al is Arg, A3 is
Phe and A11 is Gly giving rise to general formula IV: Q-Arg-A2-Phe-Thr-Leu-Ala-Ser-
Ser-Glu-Thr-Gly-A12-Gly-Z wherein the positions Q, A2, A12 and Z are as defined previously.
The most preferred peptides are selected from the group comprising desaminoargininyl-
Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-NH;, desaminoargininyl-Ser-Phe-
Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-OH, CH;-(OCH;CH,);-OCH,-C(O)-Arg-
Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-NH;, D-1-glucityl-Arg-Ser-Phe-
Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-OH, CH;0-C(O)-Arg-Ser-Phe-Thr-Leu-
Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-OH, Ac-Arg-Ser-Phe-y-[CH;NH]}-Thr-Leu-Ala- : 15 Ser-Ser-Glu-Thr-Gly-Val-Gly-NH,, Ac-Arg-Ser-Phe-Thr-Leu-y-[CH,;NH]-Ala-Ser-
Ser-Glu-Thr-Gly-Val-Gly-NH;, Ac-Arg-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-
Val-y-[CH,;NH]-Gly-NH,, Ac-Arg-N[(CH;),-OH]-CH,-C(O)-Phe-Thr-Leu-Ala-Ser-
Ser-Glu-Thr-Gly-Val-Gly- NHj, Ac-Arg-N[(CH,),-OH]-CH;,-C(O)-Phe-Thr-Leu-Ala-
Ser-Ser-Glu-Thr-Gly-Val-y-[CH,NH]-Gly- NH,, H-Arg-Ser-Phe(Cl)-Thr-Leu-Ala- Ser-Ser-Glu-Thr-Gly-Val-Gly-OH, H,N-(CH;)s-C(O)-Ser-Phe-Thr-Leu-Ala-Ser-Ser-
Glu-Thr-Gly-Val-Gly-OH, H;N-(CH,)¢-C(O)-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-
Gly-Val-Gly-OH, (N-methyl-nicotinoyl)*-Arg-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-
Gly-Val-Gly-OH.
A suitable methodology towards the synthesis of modified HC gp39 (263-275) peptides with N-terminal modifications, as visualized in Formula V, commences with derivatives of Formula VI. The modified peptides are synthesized via the commonly used Solid Phase Peptide Synthesis (SPPS) method (B. Merrifield, Solid Phase Peptide
Synthesis, Peptides 1995, 93-169, Editor: B. Gutte, Academic, San Diego, California,
USA; P. Lloyd-Williams, F. Albericio, E. Giralt, Tetrahedron 49: 11065-11133, 1993).
Depending on the type of linker that is used, the peptide chain is connected to the support via either an ester (PAC linker) or an amide (PAL linker) linkage
TR
Ap N Cc
Rp? m Formula V a I ca
A gt NS Hoa 2) 2 m = polyethylene glycol (PEG)- polystyrene (PS) solid support gq mua VI s After anchoring of the Fmoc-C-terminal amino acid to the solid support (m = 1, A-B =
Fmoc), using e.g. the coupling agents HATU (L. Carpino, A. El-Faham, C.A. Minor, F. ‘Albericio, J. Chem. Soc., Chem. Comm. 201-203, 1994) or PyBOP (J. Coste, D. Le- .
Nguyen, B. Castro, Tetrahedron Lett. 31 205-208, 1990) and DiPEA, the chain is elongated (m = 2-12) by sequential acylation with the appropriately protected Fmoc- amino acid derivatives followed by piperidine-mediated removal of the Fmoc protective group (A-B = H) using an automated peptide synthesizer. Alternatively, pentafluorophenyl (Pfp) amino acid active esters (A. Dryland, R.C. Sheppard,
Tetrahedron 44: 859-876, 1988) may be used to effect the condensations. Subsequently, the N-terminal amino acid B is introduced using the same protocol and the Fmoc-group is removed. The thus obtained 13-meric peptide derivative (A = H, B = N-terminal amino acid, m = 12) is then amenable to functionalization of the N-terminus.
Introduction of an additional amide bond at the N-terminus (A = alkylcarbonyl) can be accomplished by performing another HATU or PyBOP-mediated condensation with the desired acid (X-OH) or by coupling with an acyl chloride (X-Cl) in the presence of pyridine. The charged 1-methyl pyridinium-4-carbonyl unit or 1-methyl pyridinium-3- carbonyl unit may be introduced after cleavage (vide infra) from the resin (i.e Formula
V, A =H, B = N-terminal amino acid, Z = OR with R =H, alkyl or Z = NR'R* with R',
R? = H or alkyl) by DiPEA-mediated reaction of the free N-terminus of the completely deprotected peptide with the N-methyl (iso)nicotinium hydroxysuccinimide active ester (M.L. Tedjamulia, P.C. Srivastava, F.F. Knapp, J. Med. Chem., 28:1574-1580, 1985)
in aqueous medium (cf conversion of A = H to A = N-methyl(iso)nicotinium in
Formula V).
N-alkylation may be effected via reductive amination by treating the immobilized peptide with an appropriate aldehyde (Formula VI. conversion of A = H to A = alkyl) in the presence of NaBH(OAc); in DMF/HOAc (99/1, v/v). Alternatively, reaction of the immobilized peptide (A = H) with an alkyl halide in the presence of DiPEA also gives access to N-alkylated peptides (e.g. reaction with tert-butyl bromoacetate). The free NH; (A = H in Formula VI) may also be functionalized with a carbamoyl group (e.g methoxycarbonyl) via reaction with the corresponding carbamoyl chloride in
CH,Cl,/DiPEA (conversion of A = H to A = alkyloxycarbony! in Formula VI). After cleavage of the peptide from the solid support with concomitant removal of the acid- labile protective groups using TFA/Et;SiH/anisole/ROH (R = H, alkyl) the peptides with general Formula V (Z = OR) are purified by RP-HPLC. Alternatively, the C- terminus may be equipped with an amide function (Z = NR'R? with R' and R= H or - 15 alkyl) during cleavage from the resin. In that case, a different linker (PAL: B.
Merrifield, Peptides, 93-169, 1995) between the peptide chain (Formula VI) and the - PEG-PS solid support is used. If the free amino group of the PAL linker is alkylated prior to attachment of the first (C-terminal) amino acid, C-terminal alkyl amides will be = formed after cleavage from the polymer support. n 20 Using the same Fmoc-SPPS strategy, peptides are accessible that contain unnatural but commercially available amino acids (e.g. D-amino acids or substituted phenylalanine derivatives). Apart from this, N-alkyl glycine derivatives (peptoid monomers, R,' = amino acid side chain, R,> = H in Formulas V and VI) are first synthesized in solution using literature procedures (J.A. Kruijtzer, L.J.F. Hofmeyer, W. Heerma, C. Versluis, R.M.J. Liskamp, Chem. Eur. J. 4:1570-1580, 1998). Also the modified N-terminal amino acid B-homo-L-arginine [B = NH-CH(CH,CH,CH,NH-CH(=NH)NH;)-CH;-
C(O)] was prepared in solution prior to SPPS, according to known procedures (H.M.M.
Bastiaans, A.E. Alewijnse, J.L. van der Baan, H.C.J. Ottenheijm, Tetrahedron Lett. 35:7659-7660, 1994. After protection of the free NH; group in the thus obtained monomeric amino acids with a Fmoc protective group, the compounds can be incorporated in the elongating peptide (Formula VI) using the SPPS protocol.
The final class of modified peptides comprises peptides containing one or more reduced amide bonds (R,’ = H, in Formula V). These derivatives are accessible (J.J.
Wen, A.R. Spatola, J. Pept. Res., 49:3-14, 1997) via a modified SPPS protocol in which the free N-terminal amino acid of the growing chain (1<m<12 in Formula VI) is alkylated with the incoming amino acid aldehyde under reductive conditions (NaBH;CN, DMF/HOAc, 99/1, v/v). The required N-Fmoc protected amino acid aldehydes are either commercially available or accessible by literature methods (J.J. s Wen, C.M. Crews, Tetrahedron: Asymmetry 9:1855-1858, 1998). The thus elongated chain (A-B = Fmoc, R,! = H, R,? = amino acid side chain, R,} = H,) contains a secondary amino function (Ras)! = H) which is subsequently protected with a Boc group. After removal of the Fmoc protective group the peptide chain may be further elongated using the SPPS protocol. " Rost?
N OH
Fmoc” YO 2 1
Rn’ Ran’ © Formula VII
Alternatively, a dimeric structure with general Formula VII may be synthesized in } solution prior to SPPS. Thus, the appropriate amino acid benzyl ester (HoN-CH(Rps1)-
CO,Bzl) is reductively alkylated (NaBH3;CN, DMF/HOAc, 99/1, v/v) with a Fmoc protected amino acid aldehyde (Fmoc-NH-CH(R.%)-C(O)H) to give a dimeric secondary amine. After protection of the amino function with a Boc group (Rost! =
Boc) and subsequent hydrogenolysis of the benzyl ester a compound of Formula VII is formed, which can be incorporated into the growing chain using the SPPS procedure.
The peptides according to the invention can be used as a therapeutical substance. More particularly, they can be used for the induction of specific T-cell tolerance to an autoantigen in patients who are suffering from autoimmune disease disorders, more specifically arthritis.
Modified peptides based on a MHC class II restricted T-cell epitope structure with enhanced stimulatory activity in vitro and an enhanced activity in vivo can be selected using known technologies.
In order to maintain the agonistic properties of a given T-cell epitope it is regarded essential not to interfere too much with either the residues involved in binding to the relevant MHC molecule nor influence too much the residues involved in TCR engagement of relevant T-cells. Thus, selection of agonistic modified peptides would involve: 1) definition of the affinity of a modified peptide for binding the relevant MHC 5s molecule and comparison with the affinity of the wild type, the non-modified, peptide epitope 2) definition of the stimulatory activity of a modified peptide and comparison with the activity of the wild type, non-modified, peptide, using an in vitro assay (irradiated antigen presenting cells co-incubated with peptide antigen and specific T-cells).
Preferably a broad panel of epitope-specific, MHC class II restricted T-cells, with different TCR clonotypes, but reactive with the same epitope in the context of the same
MHC class II molecule, should be evaluated. For this purpose, a panel of specific T-cell hybridomas or specific T-cell lines/clones can be employed. Selection of a modified epitope for human application will preferably require the use of human T-cell lines/clones to safeguard the relevance of the selected modified epitopes for human T- cell recognition. 3) definition of the activity of a modified peptide in vivo (optional). For this purpose different experimental set-ups may be used a) a delayed type hypersensitivity test b) an ex vivo T-cell activation assay following the administration of antigen (with or without adjuvant) in vivo c) modulation of disease in experimental models of autoimmune disease by administration of modified peptide antigen
Preferably compounds with enhanced agonistic activity in vitro, as compared to the wild type peptide or enhanced in vivo effects are to be selected.
Individual HC gp-39 derived peptides that are being recognised in mice are expected to downmodulate reactivity towards these peptides following nasal treatment. Such reactivity can be measured by challenging the animal with the peptide in question and quantitating paw swelling as a result of a DTH response. Peptide immunisations in
Balb/c mice result in immunological responses to the HC gp-39 peptide 263-275. Thus, mice immunised with HC gp-39 can be challenged with HC gp-39 263-275 in order to detect a DTH response. To delineate tolerogenicity of modified peptides in vivo, mice can be treated per nostril with HC gp-39 263-275 or peptide derivatives in various concentrations. Modified peptide derivatives with a superior profile in terms of tolerance induction are expected to be active in this in vivo assay in lower concentrations than the original peptide. To be able to quantitatively detect effects of s tolerance induction with the native peptide versus modified peptide derivatives, various application schemes and dosages can be tested. Finally, it can be investigated whether modified forms of HC gp-39 263-275 are more effective in downmodulating HC gp-39 © 263-275 induced DTH responses in this model than the native 263-275 peptide.
Tolerance can be attained by administering high or low doses of the tolerogen or peptides according to the invention. The amount of tolerogen or peptide will depend on the route of administration, the time of administration, the age of the patient as well as general health conditions and diet.
In general, a dosage of 0.01 to 1000 pg of peptide or protein per kg body weight, : 1s preferably 0.05 to 500 pg, more preferably 0.1 to 100 pg of peptide or protein can be used.
Another aspect of the invention resides in pharmaceutical compositions comprising one or more of the peptides according to the invention and a pharmaceutical acceptable carrier.
Pharmaceutical acceptable carriers are well known to those skilled in the art and include, for example, sterile salin, lactose, sucrose, calcium phosphate, gelatin, dextrin, agar, pectin, peanut oil, olive oil, sesame oil and water. Other carriers may be, for example MHC class II molecules, if desired embedded in liposomes.
In addition the pharmaceutical composition according to the invention may comprise one or more adjuvants. Suitable adjuvants include, amongst others, aluminium hydroxide, aluminium phosphate, amphigen, tocophenols, monophosphenyl lipid A, muramy! dipeptide and saponins such as Quill A. The amount of adjuvant depends on the nature of the adjuvant itself.
Furthermore the pharmaceutical composition according to the invention may comprise one or more stabilizers such as, for example, carbohydrates including sorbitol, mannitol, starch, sucrosedextrin and glucose, proteins such as albumin or casein, and buffers like alkaline phosphates.
~ WO 01/29081 PCT/EP00/10230
Suitable administration routes are intramuscular injections, subcutaneous injections, intravenous injections or intraperitoneal injections. oral and intranasal administration.
Oral and intranasal administration are preferred administration routes. Especially, modulator cells specific for the antigen could be generated by applying the antigen via the mucosae, for instance the nasal mucosae. Mucosal administration of antigens has been shown to induce immunological tolerance to such antigens.
The peptides according to the invention are also very suitable for use in a diagnostic method to detect the presence of activated autoreactive T cells involved in the chronic inflammation of the articular cartilage.
The diagnostic method according to the invention comprises the following steps: a) isolation of the peripheral blood mononuclear cells (PBMC) from a blood sample of an individual, b) culture said PBMC under suitable conditions, c) incubation of said PBMC culture in the presence of the autoantigen or one or more peptides derived thereof according to the invention, and d) detection of a response of T cells, for example a proliferative response, indicating a the presence of activated autoreactive T cells in the individual.
In case of detection of a response by measuring the proliferative response of the autoreactive T cells, the incorporation of a radioisotope such as for example 3H- thymidine is a measure for the proliferation. A response of the autoreactive T cells present in the PBMC can also be detected by measuring the cytokine release with cytokine-specific ELISA, or the cytotoxicity with S'Chromium release. Another detection method is the measurement of expression of activation markers by FACS analysis, for example of II-2R. A diagnostic composition comprising one or more of the peptides according to the invention and a suitable detecting agent thus forms part of the invention. Depending on the type of dection, the detection agent can be a radioisotope, an enzyme, or antibodies specific for cell surface or activation markers.
Also within the scope of the invention are test kits which comprise one or more peptides according to the invention. These test kits are suitable for use in a diagnostic method according to the invention.
Thus. according to the present invention HC gp-39 derived modified peptides can be used to downmodulate autoimmune disease.
The following examples are illustrative for the invention and should in no way be interpreted as limiting the scope of the invention.
Legends to the figures
Figure 1
Proliferation of clone 235 following stimulation with lead peptide or selected modified peptides using irradiated, autologous PBMC as APCs was measured as described in example 15. Peptides were tested for their stimulatory activity in concentrations of 0, 0.4, 2, 10 and 50 pg/ml. The response of the 235 clone following stimulation with lead peptide H-Arg-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-OH (closed circles), stimulation with Ac-Arg-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val- w[CH,NH]-Gly-NH, (closed squares), stimulation with Ac-Arg-NhSer-Phe-Thr-Leu- __Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-NH2 (open circles) or stimulation with Ac-Arg- '
NhSer-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-y[CH,NH]-Gly-NH, (open squares) is shown.
Table 2
Hybridoma assay (first line t est) : + = compound stimulates all three hybridomas in a fashion comparable to or superior to the non-modified 263-275 peptide. +* = agonist activity demonstrated for 1 or 2 hybridomas but not for all three. Reactivity of human clones (proliferation of clone 235 and 243) in potency (stimulatory activity of analogue/stimulatory activity of lead peptide; e.g. HC gp-39 (263-275)). - = potency < 0.6, + = potency 0.6 -12, ++ = potency >12 - 100, +++ = potency >100. Ac-Arg-NhSer-
Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-NH,, = Ac-Arg-Ser-Phe-Thr-Leu-Ala-
Ser-Ser-Glu-Thr-Gly-Val-y[CH,NH]-Gly-NH;, D-1-Glucityl-Arg-Ser-Phe-Thr-Leu-
Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-OH, CH;5(OCH;,CH,)3;-OCH,C(O)-Arg-Ser-Phe-
Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-NH, and H-Arg-Ser-Phe(4Cl)-Thr-Leu-
Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-OH were tested for their affinity to bind HLA-
DRBI1*0401 and compared to the affinity of the lead-peptide (H-Arg-Ser-Phe-Thr-Leu-
Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-OH). The most active compounds (Ac-Arg-NhSer-
Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-NH> and Ac-Arg-Ser-Phe-Thr-Leu-
, WO o1/29081 PCT/EP00/10230
Ala-Ser-Ser-Glu-Thr-Gly-Val-y[CH,NH]-Gly-NH;) showed a relative affinity for binding to HLA-DRB1*0401 which was comparable to the affinity of the original peptide.
Example 1
H-Arg-Ser-Phe(4Cl)-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-OH (1)
The reaction vessel of the Millipore 9050 PepSynthesizer was charged with 0.5 g of
Fmoc-Gly-PAC-PEG-PS (commercially available at PerSeptive Biosystems, 0.20 mmol/g) resin, pre-swollen in N-methyl-pyrrolidinone (NMP). Removal of the Fmoc group in each coupling cycle was effected with piperidine/DMF (1:4 v/v). The coupling efficiencies were determined by spectroscopic analysis of the Fmoc-cleavage after each : elongation step. In each coupling step 4 equivalents of the appropriate acid-labile side- chain-protected Fmoc amino acid were used. The double syringe mode of the synthesizer was used in which one syringe contains 0.50 M HATU in DMF p.a. and the other syringe contains 1.0 M DIPEA in DMF p.a. The main wash contained N-methyl- pyrrolidinone with 0.1% HOBt. The Analog Synthesis protocol was used. After removal of the final Fmoc group the resin with the immobilized peptide was taken out of the reaction vessel and washed successively with DMF (20 mL), CH,Cl; (20 mL), diethylether (20 mL), CH,Cl; (20 mL), diethylether (20 mL), CHCl, (20 mL) and diethylether (20 mL). The immobilized peptide was dried in vacuo overnight. The peptide was then cleaved off with 10 mL of the mixture TFA/(iPr);SiH/anisole/H,O 88/5/5/2 v/v/vlv for 3 hours. In this step all the acid-labile side-chain protective groups were also removed. After evaporation of the solvent the peptide was precipitated with 200 mL of diethyl ether. The ether layer was decanted and the peptide was washed with an additional amount (2 x 200 mL) of ether. The crude peptide was then dried with a stream of nitrogen and lyophilized. Purification of the peptide was carried out by HPLC chromatography on a PrepPak cartridge 40-100 mm Delta-Pak™ C18 15 pm 100A reverse phase column. The mobile phase consisted of a mixture of 20% of phosphate buffer pH 2.1 and a gradient of acetonitrile and water, as shown in the analysis below.
The peptide was desalted on the HPLC, using 4° aqueous acetic acid. The purified product was lyophilized.
Mobile phase: A: 0.5 mol/L NaH;PO4 + H;PO,, pH=2.1
B: H,O
C: CH3CN/H,0 = 3/2 (v/v) gradient: A: 20%: B: 80% — 20%; C: 0% — 60% in 40 min.
Yield: 68 mg; HPLC purity: 90.1%; MS: MW = 1346, this agrees with the molecular formula CssHggCIN6O;1; amino acid analysis: all amino acids were found in the required amounts; peptide content: 74.8%; ion chromatography: phosphate: 0.6%, acetate: 0.6%, chloride: 3.4% (w/w).
Example 2
H;N-(CH,)s-C(O)-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-OH 2)
The peptide was synthesized using solid phase peptide chemistry, as reported in the synthesis of compound 1 (see above). In this case, commercially available Fmoc-amino acid pentafluorophenyl (Pfp) active esters were used instead of the free Fmoc-amino acids and HATU/DIPEA. The compound was prepared using 6-Fmoc-amino-hexanoic acid as the N-terminal amino acid, obtained from 6-amino-hexanoic acid, analogous to the literature procedure (A. Marston, E. Hecker, Z. Naturforsch. B Anorg. Chem. Org.
Chem., 38:1015-1021,1983). The support was Fmoc-Gly-PAC-PEG-PS (0.75 g, 0.170 mmol/g) and 3 equiv. Of the appropriate Pfp esters were used. For the coupling of 6-
Fmoc-amino-hexanoic acid PyBOP was applied as the coupling agent (199 mg).
Workup as reported in the standard procedure (example 1) gave 168 mg of crude product. This was purified by HPLC (phosphate system pH=2.1, with CH3CN-H,0O gradient). The product was desalted on the HPLC with 5 °/, aqueous acetic acid and 25s freeze-dried to give 34 mg of the required peptide.
HPLC purity: 99.6%; MS: MW = 1268, this agrees with the molecular formula
CssHgoNj3021; amino acid analysis: all amino acids were found in the required amounts; peptide content: 67.3%; ion chromatography: phosphate: 10% (w/w).
Example3
H:N-(CH,)¢-C(O)-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-OH (3)
Peptide 3 was prepared in an identical fashion as its N-terminal homolog 2 using 7-
Fmoc-amino-heptanoic acid (3a, prepared analogous to compound 2a: A. Marston, E.
Hecker, Z. Naturforsch. B Anorg. Chem. Org. Chem., 38:1015-1021, 1983) as the N- terminal amino acid. The support was Fmoc-Gly-PAC-PEG-PS (1.0 g, 0.17 mmol/g).
Workup, HPLC purification and desalting as reported in the standard procedure (example 1) gave 45 mg of the required peptide.
HPLC purity: 95.0%; MS: MW = 1282, this agrees with the molecular formula
Cs¢HoiN30,; amino acid analysis: all amino acids were found in the required amounts; peptide content: 87.4%; ion chromatography: acetate: 0.2% (w/w).
Example 4 (N-methyl-nicotinoyl) -Arg-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-
OH (4) - 15 Prior to the preparation of peptide 4, the starting material N-succinimidy! (1-methyl-3- pyridinio)formate iodide (4a) was synthesized via a literature procedure (M.L.
Tedjamulia, P.C. Srivastava, F.F. Knapp; J. Med. Chem. 28:1574-1580, 1985). The synthesis of compond 4 was carried out in solution. The peptide H-Arg-Ser-Phe-Thr-
Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-OH (4b, 26 mg, 0.02 mmol), prepared by SPPS methods according to example 1, was dissolved in DMF/H,0 (1/99 v/v, 10 mL) and
DIPEA/DMF (1/1, v/v) was added to give pH=9. Then N-succinimidyl (1-methyl-3- pyridinio)formate iodide (4a, 0.056 g. 0.15 mmol) was added in two portions. The pH was kept at pH=9 by adding a few drops of DIPEA/DMF (1/1, v/v). The mixture was stirred at room temperature for 4 hours and then diluted with 10 mL of HO and 5 mL of phosphate buffer pH=2.1. The product was purified immediately by HPLC with the phosphate buffer system as shown previously (example 1). Desalting with 5°,, aqueous acetic acid and lyophilisation provided 14 mg of the required peptide 4.
HPLC purity: 98.1%; MS: MW = 1430; amino acid analysis: all amino acids were found in the required amounts; peptide content: 56.3%; ion chromatography: chloride: 1.4%, phosphate: 1.0%, trifluoroacetate: 0.8%, acetate: 0.3% (w/w).
Desaminoargininyl-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-OH (5)
Peptide 5 was synthesized according to the previously described procedure for compound 1 using Fmoc-protected amino acids, HATU, DIPEA and 1.0 g of Fmoc-
Gly-PAC-PEG-PS-resin. support loading 0.17 mmol/g. In the final step desamino-
Arg(Adoc),-OH (5a) was coupled to the immobilized peptide chain. Carboxylic acid Sa was prepared according to a known procedure (R. Presentini, G. Antoni, Int. J. Pept.
Protein Res., 27:123-126, 1986). Workup and purification conditions were identical to those of peptide 1.
Yield: 58 mg; HPLC purity: 91.1%; MS: MW = 1296; amino acid analysis: all amino acids were found in the required amounts; peptide content: 76.2%; ion chromatography: phosphate: 0.4%, trifluoroacetate: 0.6%, acetate: 0.2% (w/w).
Example 6
Desaminoargininyl-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-NH; (6)
The assembly of peptide 6 was conducted in a fashion similar to that of previously : described peptide 5, using PAL-PEG-PS resin (0.17 mmol/g) instead of PAC-PEG-PS as the solid support. In this case, the Fmoc group from commercially available (PerSeptive Biosystems) Fmoc-PAL-PEG-PS resin was removed and the resulting H-
PAL-PEG-PS support was condensed with Fmoc-Gly-OH under the agency of
HATU/DIPEA. After elongation of the peptide chain and subsequent cleavage from the resin under the same conditions as described in example 1, the required carboxamide
C-terminus was obtained. Workup and purification conditions were identical to those of peptide 1.
Yield: 43 mg; HPLC purity: 91.3%; MS: MW = 1295; amino acid analysis: all amino acids were found in the required amounts; peptide content: 76.5%; ion chromatography: chloride: 0.5%, acetate: 4.0% (w/w).
Example 7
CH;3(OCH,CH;);-OCH,-C(0O)-Arg-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-
Val-Gly-NH; (7)
For the synthesis of peptide 7 the starting material CH3(OCH;CH3);-OCH,-CO,H (7a) was prepared first, according to a literature procedure (A.H. Hames, P. Karntiang,
Carbohydr. Res.. 78:205-211, 1980). The synthesis of the protected and immobilized peptide ~~ H-Arg(Pmc)-Ser(tBu)-Phe-Thr(tBu)-Leu-Ala-Ser(tBu)-Ser(tBu)-Glu(OtBu)-
Thr(tBu)-Gly-Val-Gly-PAL-PEG-PS (7b) was conducted as shown in example 2 using amino acid Pfp esters. The peptide on the resin (7b) was pre-swollen in NMP and 142 mg (0.64 mmol) of CH3(OCH,CH,;);-OCH,CO,H (7a) was added, together with 169 mg (0.64 mmol) of the coupling agent TFFH (tetramethylfluoro-formamidinium hexafluorophosphate). The combined reagents were circulated during 60 minutes in de
Pepsynthesizer. Cleavage from the resin and workup were executed as described in example 5. The crude peptide was then purified by HPLC with the system and solvents delineated in example 1. The product was desalted on the HPLC column using 2.5%, of AcOH.
Yield: 120 mg; HPLC purity: 78%; MS: MW = 1515; ion chromatography: chloride: 0.1%, phosphate: 0.3%, trifluoroacetate: 4.0%, acetate: 0.3% (w/w). 1s Example 8 : D-1-glucityl-Arg-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-OH (8)
Prior to the assembly of N-terminally modified peptide 8, the peptide H-Arg(Pmc)-
Ser(tBu)-Phe-Thr(tBu)-Leu-Ala-Ser(tBu)-Ser(tBu)-Glu(OtBu)-Thr(tBu)-Gly-Val-Gly-
PAC-PEG-PS (8a), having the same sequence as peptide 7b but differing in the type of linker (PAC instead of PAL), was prepared according to example 1. Reductive amination was effected by overnight treatment of 6-O-trityl-a/B-D-glucopyranose (8b, 422 mg, 1.0 mmol, T. Utamura, K. Kuromatsu, K. Suwa, K. Koizumi, T. Shingu,
Tetsuro; Chem. Pharm. Bull. 34:2341-2353, 1986) with the immobilized peptide 8a (500 mg, 0.2 mmol/g) in DMF/HOACc (99/1, v/v, 10 mL) using NaBH(Oac); (212 mg, 1.0 mmol) as the reducing agent. Subsequent cleavage of the resulting fully protected derivative (6-O-trityl-D-1-glucityl)-Arg(Pmc)-Ser(tBu)-Phe-Thr(tBu)-Leu-Ala-
Ser(tBu)-Ser(tBu)-Glu(OtBu)-Thr(tBu)-Gly-Val-Gly-PAC-PEG-PS from the resin using the conditions described in example 1, with concomitant removal of the trityl group and all amino-acid-protecting groups, furnished 38 mg of the target peptide 8, after purification by preparative HPLC and desalting with 5 %. aqueous HOAc.
HPLC purity: 84.7%; MS: MW = 1475; amino acid analysis: all amino acids were found in the required amounts; peptide content: 61.0%; ion chromatography: chloride: 0.1%, acetate: 1.7% (w/w).
Example 9
MeO-C(0)-Arg-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-OH (9)
The synthesis of peptide 9 commenced by suspending the immobilized peptide H- 5s Arg(Pmc)-Ser(tBu)-Phe-Thr(tBu)-Leu-Ala-Ser(tBu)-Ser(tBu)-Glu(OtBu)- Thr(tBu)-
Gly-Val-Gly-PAC-PEG-PS (8a) in dioxane and cooling to 0 °C. To this suspension, 100 pl of 4N aq NaOH and 100 pl of methyl chloroformate were added. The reaction mixture was agitated for 16 h and subsequently, the resin was washed with EtOH/H;O0,
EtOH, CH,Cl, and ether. After drying in vacuo, the product was cleaved off the resin and purified as described in the previous peptide syntheses (example 1). Finally, the peptide was desalted on the HPLC using 5%, of aqueous acetic acid and then lyophilized to give peptide 9. : Yield: 11 mg; HPLC purity: 96.8%; MS: MW = 1368; amino acid analysis: all amino acids were found in the required amounts; peptide content: 60.5%; ion chromatography: chloride: 2.0%, phosphate: 0.2%, acetate: 0.4% (w/w).
Example 10
Ac-Arg-Ser-Phe-Thr-Leu-y[CH,;NH]-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-NH; (10)
Prior to the synthesis of peptide 10, the required amino acid aldehyde building block
Fmoc-Leu-H (10a) was prepared via a known procedure (J.-P. Meyer, P. Davis, K.B.
Lee, F. Porreca, HI. Yamamura, V. Hruby, J. Med. Chem. 38:3462-3468, 1995).
Compound 10a was used without further purification. According to the method described in example 1, the resin was functionalized with an 8-amino acid peptide chain to give H-Ala-Ser(tBu)-Ser(tBu)-Glu(OtBu)-Thr(tBu)-Gly-Val-Gly-PAL-PEG-
PS (10b). The latter immobilized derivative (1 g, 0.2 mmol/g) was suspended in 5 mL of 1% acetic acid in DMF. Two solutions were prepared, being 148 mg of Fmoc-Leu-H (10a) in 2.5 mL of DMF and 30 mg of NaCNBHj in 2.5 mL of DMF. Both solutions were combined and added to the suspension of peptide 10b. The mixture was agitated overnight at room temperature. Subsequently, the thus obtained intermediate Fmoc-
Leu-y[CH;NH]J-Ala-Ser(tBu)-Ser(tBu)-Glu(OtBu)-Thr(tBu)-Gly-Val-Gly-PAL-PEG-
PS (10c¢) was protected at the newly introduced secondary amine function with Boc,O and pyridine. The resin-bound peptide 10¢ was suspended in 10 mL of dry CHCl, and mg (0.16 mmol) of Boc,0 and 13 pl (0.16 mmol) of pyridine were added. The pH was kept at pH=8 with pyridine and the mixture was agitated overnight. Workup involved washing of the resin with CH,Cl,, EtOH, CH,Cl,, ether and drying in vacuo.
The synthesis was continued by SPPS using Fmoc amino acids and the HATU/DIPEA protocol with NMP as the solvent (example 1). The last step involved coupling with 4- nitrophenyl acetate to introduce the N-terminal acetyl group. After workup as described in example 1, the crude peptide was purified by HPLC, desalted with 5 %g of acetic acid and freeze-dried to give the target peptide 10.
Yield: 28 mg; HPLC purty: 76.3%; MS: MW = 1339; ion chromatography: trifluoroacetate: 1.2%, acetate: 2.0% (w/w).
Example 11
Ac-Arg-Ser-Phe-y[CH;NH]-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-NH; (11)
The synthesis of 11 involved the reductive coupling of Fmoc-Phe-H (11a, J.-P. Meyer,
P. Davis, K.B. Lee, F. Porreca, HI. Yamamura, V. Hruby, J. Med. Chem., 38:3462- : 15 3468, 1995) to the resin-bound protected peptide H-Thr(tBu)-Leu-Ala-Ser(tBu)-
Ser(tBu)-Glu(OtBu)-Thr(tBu)-Gly-Val-Gly-PAL-PEG-PS (11b) obtained via the SPPS protocol described in example 1. Peptide 11b (1.0 g, 0.2 mmol/g) and aldehyde 11a (200 mg) were suspended in 5 mL of 1% acetic acid/DMF and immediately 30 mg (0.48 mmol) of NaCNBHj;, dissolved in 5 mL of DMF, was added. The mixture was stirred for 16 h, resulting in the formation of Fmoc-Phe-y[CH,NH]-Thr(tBu)-Leu-Ala-
Ser(tBu)-Ser(tBu)-Glu(OtBu)-Thr(tBu)-Gly-Val-Gly-PAL-PEG-PS. The peptide chain was then elongated with the appropriate Fmoc-amino acids and N-terminal acetylating agent using the HATU/DIPEA SPPS protocol as described in example 8. Workup,
HPLC-purification and desalting were carried out as described in example 1.
Yield: 52 mg; HPLC purity: 97.9%; MS: MW = 1338; amino acid analysis: all amino acids were found in the required amounts; peptide content: 92.4%; ion chromatography: acetate: 2.5% (w/w).
Example 12
Ac-Arg-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-y[CH,;NH]-Gly-NH, (12)
For the synthesis of this compound, it was impossible to carry out the reductive alkylation with Fmoc-Val-H on the resin. Therefore, the dipeptide analogue Fmoc-Val-
y[CH;NH]-Gly-OH (12d) was prepared in solution prior to immobilization to the resin.
Fmoc-Val-y[CH;NH]-Gly-Obazl (12¢) 5s Fmoc-Val-H (12a, 3.16 g, 10 mmol, prepared according to T. Moriwake, S.-I. Hamano,
S. Saito, S. Torii, S. Kashino, J. Org. Chem., 54:4114-4120, 1989) was dissolved in
EtOH/HOAc (80 mL, 99/1, v/v) and HCI1.H-Gly-Obzl (12b, 2.02 g, 10 mmol) was added, followed by NaCNBH; (0.94 g, 15 mmol). The reaction mixture was stirred at room temperature overnight. Subsequently, 5% aq. NaHCO; (20 mL) was added to neutralize the reaction mixture. The mixture was then concentrated in vacuo and the residue was extracted with CH,Cl,. The combined organic layers were washed with satd. Aq. NaCl, dried quickly over Na;SOy, filtered and the solvent was evaporated to yield a yellow oil After purification by silica gel chromatography (eluent: 0-4% methanol in CH,Cl,) compound 12¢ was isolated as a white solid. Yield: 1.85 g (39 %). :
Analysis: TLC: (silica, CH,Cl,/MeOH 98/2) Rf = 0.45, MS: MW = 472,
Fmoc-Val-y[CH;N(Boc)]-Gly-Obzl (12d)
Fmoc-Val-y[CH,NH]-Gly-Obz! (12¢, 0.910 g, 1.93 mmol), Boc,O (0.420 g, 1.93 mmol) and DIPEA (0.336 g, 1.93 mmol) were dissolved in dry CH,Cl; (20 mL). The pH was kept basic by addition of DIPEA and the mixture was stirred overnight at room temperature. The reaction mixture was then acidified by addition of 10% KHSO,.
Water was added and the aqueous layer was extracted with CH,Cl;. The combined organic layers were washed with aq. Satd. NaCl, dried quickly over MgSOy and the solvent was evaporated to yield 0.96 g (97%) of 12d. Analysis: TLC: (silica,
CH,Cl/MeOH 98/2) Rf = 0.55; MS: MW=572.
Fmoc-Val-y[CH;N(Boc)}]-Gly-OH (12¢)
Fmoc-Val-y[CH,N(Boc)]-Gly-Obzl (12d, 0.97 g, 1.70 mmol) was dissolved in a mixture of MeOH/EtOAc (1/1, v/v, 100 mL) and hydrogenated at normal pressure with 10% Pd/C for a time of 2 h. The palladium catalyst was filtered off and the filtrate was concentrated to afford carboxylic acid 12e as a slightly yellow oil. Yield: 0.661 g
(81%). Analysis: TLC (silica. CH,Cl/MeOH/AcOH 90/9/1) Rf = 0.42: MS: MW = 482.
Using the Peptide synthesizer with HATU/DIPEA double syringe mode and with a double coupling with HATU/DIPEA, the compound Fmoc-Val-y[CH;N(Boc)]-Gly-
OH (12¢) (0.661 g, 1.37 mmol) was loaded onto PAL-PEG-PS resin (1.5 g, 0.15 mmol/g, 0.225 mmol). The substitution level was measured with the standard Fmoc cleavage procedure and was 0.13 mmol/g of loaded resin (yield: 87%). The resulting peptide H-Val-y[CH:N(Boc)]-Gly-PAL-PEG-PS (12f) was further elongated using the lo. HATU/DIPEA SPPS protocol (example 1) with double condensation steps of 60 min for each Fmoc-amino acid. Similar to peptides 9 and 11 the N-terminal acetyl group was introduced using 4-nitrophenyl acetate. Workup, purification and desalting were carried out as described in example 1. : Yield: 17 mg; HPLC purity: 80.1%; MS: MW = 1338; amino acid analysis: all amino acids were found in the required amounts; peptide content: 63.7%; ion chromatography: chloride: 1.0%, phosphate: 0.2%, acetate: 0.2% (w/w).
Example 13 : Ac-Arg-NhSer-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-NH; (13)
For the synthesis of peptide 13 the requisite peptoid monomer Fmoc-NhSer(tBu)-OH (13e) was prepared first.
Z-2-aminoethyl-tert-butyl ether (13a) 3.25 g MgS04 (27 mmol) was suspended in 80 mL of CH,Cl, (dry). Under N; 1.5 mL of conc. H;SO4 was added (procedure: S.W. Wright, D.L. Hageman, A.S. Wright, L.
McClure, Tetrahedron Lett., 38:7345-7348, 1997). The mixture was stirred for 15 min after which tert-BuOH (12.9 mL) and commercially available Z-2-aminoethanol (5.28 g, 27 mmol), dissolved in CH,Cl, (20 mL), were added. After stirring for S days, 200 mL of 5% aq. NaHCO; was added to the reaction mixture, which was stirred until all the MgSO4 had dissolved. The layers were separated and the CH,Cl, layer was washed with brine. The organic layer was dried over MgSO, filtered and the solvent was evaporated to yield 5.6 g of crude 13a. The product was purified by column chromatography (eluent: heptane/EtOAc 3:1 v/v). Yield 5.00 g (78%). 'H NMR (CDCl) 3: 1.15 (s, 9H, tBu), 5.3-3.5 (dt, 4H, 2 x CH), 5.1 (bs, 2H, CH,Bzl), 7.4 (m, 5H, Ar). 5s 2-aminoethyl-tert-butyl ether. HCI (13b)
To a solution of 5.00 g of benzyl ester 13a in ethyl acetate (150 mL) 225 mg of 10%
Pd/C was added and H; was bubbled through for 2 hours. The catalyst was filtered off and 15 mL of 1 M aq. HC] was added. The solvent was evaporated and a small volume of ether was added. The precipitated product 13b was filtered off and dried in vacuo.
Yield: 2.35 g (77%). NMR (CDCl) 6: 1.20 (s, 9H, tBu), 3.15 (t, 2H, CHy), 3.65 (t, 2H
CH,), 8.1-8.4 (bs, 2H. NH;)
N-(2-fert-butoxyethyl)-glycine (H-NhSer(tBu)-OH) (13¢)
To a solution of 13b (2.30 g, 15 mmol) in 25 mL of H,O was added 1.40 g (15.2 mmol) : of glyoxylic acid. H,O. The pH was adjusted to pH=6 with 1.0 M aq NaOH. To this solution 230 mg of Pd/C was added and the reaction mixture was agitated at 45 psi H; pressure overnight. The catalyst was filtered off and washed with 5 mL H,0. The filtrate containing 13c was used without further purification in the next step.
Fmoc-NhSer(tBu)-OH (13d)
The reaction product 13c, still dissolved in H,O, was brought to pH=9.5 with 1 N
NaOH. The basic solution was diluted with 25 mL of acetone and 5.40 g (16 mmol)
Fmoc-Osu, dissolved in 25 mL of acetone, was added dropwise. The pH was kept at pH=9.5 with 1 N NaOH. After stirring overnight, the reaction mixture was concentrated to 150 mL and washed with 2 x 50 mL of ether/heptane (1/1, v/v). The
H,0 layer was acidified to pH = 2.5 with 20% citric acid and 3 x extracted with 100 mL of ethyl acetate. The organic layers were combined and dried over Na,SO4. The solvent was evaporated and the product was purified by column chromatography (silica, CH,Cl,/MeOH 5/1, v/v) and freeze-dried. Yield: 5.44 g (91 %). 'H NMR (CDCl) 8: 1.20 (s, 9H, tBu), 3.2 (dt, 2H CH»), 3.6-3.7, (dt, 2H, CH), 4.05 (s, 2H,
CH,CO,H), 4.2 (b, 1H Fmoc), 4.4-4.6 (2H, 2 x d, Fmoc), 7.3-7.8 (m, 8H, ArH, Fmoc).
~ WO 01/29081 PCT/EP00/10230
The synthesis of peptide 13 was carried out on the Pepsynthesizer using the dual syringe technique as described before (example 1). The support was Fmoc-PAL-PEG-
PS, (1.0 g, 0.15 mmol/g) with NMP as the solvent. Double couplings (coupling time 60 min) were used for all amino acids. including Fmoc-NhSer(tBu)-OH (13d). The N- terminal acetyl group was introduced using 4-nitrophenyl acetate. Workup and cleaving off the resin and protecting groups were conducted in the standard way (example 1).
The crude peptide was purified by HPLC and desalted with 5°, of aqueous acetic acid.
Yield: 50 mg; HPLC purity: 98.6%; MS: MW = 1366; amino acid analysis: all amino acids were found in the required amounts; peptide content: 82.1%; ion chromatography: chloride: 0.3%, acetate: 1.3% (w/w).
Example 14
Ac-Arg-NhSer-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-y[CH;NH]-Gly-NH; (14) . 1s The synthesis was carried out using the HATU/DIPEA protocol on the Pepsynthesizer (example 1). The previously described functionalized resin H-Val-y[CH;N(Boc)]-Gly- - PAL-PEG-PS (12f) and the protected peptoid Fmoc-NhSer(tBu)-OH (13d) were used as building blocks. As described before, the dual syringe technique and double couplings of 60 min per coupling were used. Elongation of the peptide chain on the synthesizer was stopped before the coupling of Fmoc-NhSer(tBu)-OH (13d) and this amino acid was dissolved in DMSO with sonication prior to coupling to the immobilized peptide chain (H-Phe-Thr(tBu)-Leu-Ala-Ser(tBu)-Ser(tBu)-Glu(OtBu)-
Thr(tBu)-Gly-Val-yw[CH,NH]-Gly-PAL-PEG-PS). The synthesis was finished by condensation of the remaining (Arg) amino acid and acetylation using 4-nitrophenyl acetate. Workup, purification and desalting of the peptide were standard, as outlined in example 1. Lyophilization furnished 47 mg of peptide 14.
HPLC purity: 72.9%; MS: MW = 1352; ion chromatography: trifluoroacetate: 5.5% (w/w).
Example 15
Pre-selection of agonist peptides using antigen-specific T-cell hybridomas (first line test).
To test the agonist activity of a modified peptide, 3 different, HC gp-39 (263-275)- s specific hybridoma cell lines were used (5G11. 8B12 and 14G11). 5 x 10* hybridoma cells and 2 x 10° irradiated (12000 RAD), EBV-transformed B cells carrying the
DRB1*0401 specificity were incubated in 150 pl volumes in wells of a round- bottomed microtiter plate. Peptide antigen (HC gp-39 (263-275), and modified peptides) was added in 50 pl volumes to duplicate wells. Forty eight hr later 100 pul of the culture supernatant was assayed for antigen-specific IL-2 production using a sandwich ELISA with Pharmingen antibodies specific for mouse IL-2.
Selection of agonist peptides using antigen-specific T-cell clones (second line test)
The 243 T-cell clone was isolated from a peptide-specific T-cell line obtained from an
RA responder to peptide 263-275 (RA patient 243). The clones were obtained following four repetitive stimulations with HC gp-39 (263-275) peptide in the presence of DRB1*0401-matched PBMC. The H235 T-cell clone was isolated from a peptide- stimulated T-cell line obtained from an HLA-DRBI1*0401-positive donor. Upon 2 stimulations with peptide HC gp-39 (261-275) in the presence of DRB1*0401-matched
PBMC, clones were obtained by PHA cloning. Both clone 243 and 235 were found to be HLA-DRB1*0401 restricted in the recognition of peptide antigen. Cells were used on day 10-14 after stimulation in each experiment.
Proliferative responses of clone 243 or clone 235 were measured by incubation of 2 x 10* T cells and 10° DRB1*0401-matched (3,000 Rad irradiated) PBMC in 150 pl volumes of medium with 10% normal human pool serum (NHS, CLB, Amsterdam, The
Netherlands) in flat-bottomed microtiter plates. 50 ul of antigen solution (containing the 263-275 sequence or modifications as indicated) was distributed in triplicate wells. 3H-thymidine was added at day 2 or 3 of incubation. Cells were harvested on glass fibre filters and the incorporated radioactivity was measured.
Results
Most modified peptides as listed in Table 2 were able to stimulate all three T-cell hybridomas in a fashion comparable to the lead peptide H-Arg-Ser-Phe-Thr-Leu-Ala-
Ser-Ser-Glu-Thr-Gly-Val-Gly-OH. Some peptides, however, did not stimulate all three hybridomas which exemplifies the difference in specificity of the hybridomas used.
When these agonists were tested for their capacity to stimulate the two human T-cell clones. a clear difference in potency of the compounds tested became obvious (Table 2). Most modified compounds induced a response of clone 235 and clone 243. One compound (Ac-Narg-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-NH2) did not induce a proliferative response of either clone. Three compounds (H- betahomoargininyl-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-OH, Ac-Arg-
Ser-Phe-y[CH2NH]-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-NH, and Ac-Arg-Ser-
Phe-Thr-Leu-y[CH2NH]-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-NH,;) were active on one clone only (either clone 243 or 235). Three compounds (H-Arg-Ser-Phe(4Cl)-Thr-Leu-
Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-OH, H-D-Arg-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-
Thr-Gly-Val-Gly-OH and CH30C(O)-Arg-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-
Val-Gly-OH) induced a proliferative response in both clones which was in the same order of magnitude as the response induced by the lead peptide H-Arg-Ser-Phe-Thr-
Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-OH. Seven compounds (Ac-Arg-Ser-Phe-Thr- oo - 15 Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-OH, CH3(OCH;CH,);-OCH,C(0O)-Arg-Ser- . Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-NH,, D-1-glucityl-Arg-Ser-Phe-Thr- ; . Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-OH, (N-methyl-nicotinoyl)*-Arg-Ser-Phe-Thr-
Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-OH, Ac-Arg-Ser-Phe-Thr-Leu-Ala-Ser-Ser- + Glu-Thr-Gly-Val-y[CH,NH]-Gly-NH;, Ac-Arg-NhSer-Phe-Thr-Leu-Ala-Ser-Ser-Glu- = Thr-Gly-Val-Gly-NH; and Ac-Arg-NhSer-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val- g y[CH,NH]-Gly-NH;) were superior in inducing a proliferative response of one or both clones. The most potent compounds identified being Ac-Arg-Ser-Phe-Thr-Leu-Ala-
Ser-Ser-Glu-Thr-Gly-Val-Gly-OH, Ac-Arg-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-
Gly-Val-y[CH;NH]-Gly-NH;, Ac-Arg-NhSer-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-
Val-Gly-NH, and Ac-Arg-NhSer-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val- y[CH:;NH]-Gly-NH; (Table 2 and Figure 1).
Example 16
Female Balb/c mice of approximately 8-10 weeks of age (Charles River Germany or
Charles River France) were immunised on day 0 with 100 ul of antigen preparation (50 ug of HC gp-39 263-275) in Incomplete Freunds Adjuvant (IFA; Sigma Chemicals, St.
Louis, USA). Antigen was given subcutaneously in two portions in the chest region of the mice. On day 7, mice were challenged with antigen preparation (HC gp-39 (263- 275)) diluted in 0.9% NaCl (NPBI, Emmer Compascuum, The Netherlands) in a volume of 50 ul in I mg/ml alum (Pharmacy Donkers-Peterse, Oss, The Netherlands)
unilaterally in the footpad (left paw); the other (right) footpad was injected with 50 pl of alum solution in 0.9% NaCl as a control. Delayed type hypersensitivity responses (mean % specific swelling) were determined on day 8 by measuring the increase in footpad thickness of the left hind footpad compared to the right hind footpad (swelling left (mm) - swelling right (mm) / swelling right (mm) x 100%), using a in-house designed micrometer.
Nasal application of antigen preparation (50, 10, 2 or 0.4 pg (or lower concentrations)) of HC gp-39 (263-275) or of modified peptide derivatives was performed under
Isoflurane (Forene®, Abbott BV, Amstelveen, The Netherlands) anesthesia once (day - 5) before immunisation on day 0 with 100 pl of antigen preparation containing 50 ug of
HC gp-39 263-275 in IFA. In these experiments, mice were immunised and challenged with HC gp-39 263-275 and DTH responses were determined as described above.
Using the above described assay system in which Balb/c mice immunised with HC gp- 39 (263-275) in IFA responded to HC gp-39 (263-275), it became possible to study the ) potential effects of tolerance induction by nasal application of HC gp-39 (263-275) in comparison to those of modified peptide derivatives. Pre-treatment with HC gp-39 (263-275) downmodulated the HC gp-39 (263-275) specific DTH reaction; this effect was dependent on the dose of peptide that was included in the pre-treatment procedure.
Using a relatively high peptide concentration (50 pg/mouse), nasal application of one dose of HC gp-39 (263-275) fully abrogated the DTH reaction whereas a dose of 2 ug/mouse was ineffective. Thus, a protocol was established to discriminate between effective (tolerogenic) and ineffective doses of peptide in a HC gp-39 (263-275) specific DTH assay system. Assuming that modified peptide derivatives based on HC gp-39 (263-275) may be active at lower concentrations than the original peptide, such peptides are expected to induce tolerance at relatively low peptide concentrations.
Following this assumption, a series of modified peptides was tested in this tolerance induction protocol. In this experiment (in which a reliable HC gp-39 (263-275) response was induced that could be downmodulated by pre-treatment with 50 but not 2 ug of HC gp-39 (263-275)) it was shown that specific modifications of the peptide were highly active in the induction of tolerance whereas others were not (see Table 3).
wl 7
L
~~ >
[3] 12]
[72] © oO = ae EEE: © =} 11
S 5 8S ++ 22+ 28 TIF + 2.8 . < > © 8 =5 ye = ry —
S 3 E i 8 S| © TE: + =} 11
L oS F aN] + + £2 2 + 2 = + ++ + + + + ‘ [@} o fn) [34 = g fed [@] 3 a=) = = = |S ®
[9] >» 9 * * 0» = I + +++ ++ +++ +++ +++ +++ ++ a) jl
Lo S
S " y ~ z = 2 : = a > = ost 2 > 9 = 8 =r 5 0 SEFEE % [@] ) g 5 LI __3%ZZz = =) 323 Ezx>2Fozxzzxz2> hl 3 CIS) £939 Tt 00QQ T — fools of I YY S202 55s 2 OZ 50 O%% 9359GCT SEs > IL A> > zs EIRTTRZILE
Q QI 1050835722 599z022 2 £ > 28 LL L50 202k EEL SYS = S5>>050> E2973 YO LE T > 3 = QT 29 LEEZT Ys 2R ROSS 2 T5050 2ASTEREDZERSLEE = 2 LL E0020 853599252259 ¢ 2 3 2 EXA2T T2820 28 558550 = = 5 = = © : 9 vO OT = 5 = CRT 88 L039 509 Lak k o £22529 2255855888 4 3 = EOQEQOSSRE LT Jdrsusdabll sds
J - YT rE fw 23 P29 Y 5520900
Q 28828 5852382253695 8 = DRP0L22F LReED CCT TV 500 8 UR BRR ORION SCI IRA I Sl BO 2 34%4%383F ps2 72555%7% a se <S<LES<EESE ELSES SE 1%] T= = + 0 PW a TF = = 2 te iE sAT se E0 ss TT 0 <2 TILT EE s QE alls 5 5 5303 = 3 2 cc 3 £2 7 0 uv Q 0 © “LH OD 0 3 WL
Smt ° o = ZT 2 < = wn aa an =~ = 8 oo = ) fe LL = ° SLi eB REL T 30 LL ERE 2 158 EL1iE558E5FEER 2 s |g FISEEZEL S229 E 1,0 020 RE
E 2 OT 8 8S BEES XL WE PRPS Sq gg
E |2 EEESL 230 <E<CEXTTT SES 3 hoe LLL SMES SITS O0FES SSIES wn 4] S88 IS 22NPRELLSRRRAL LEZ oN = paw A EERO SLE RRS PR
Oo — PREPRESS ETES OD € € CC Z << — [oW fcc TST ro2@@EBETTLTATS a 9) Cr rr Oe ol T2381 QC QQ Qo 99 = a TIT TITITrTIT<cnoa<c0A&Erag<c <<< <<
~~ 2 u ~~ ore)
S S
50 = 3S
C2 ol o = o S&S oa |s = 5 3 = = =3%2 =9 w= = 2 |B iro) - [= co } oo > > > .
Te S20 a® . 87.092 72 Ss Ss oS = . . - 1S het Lr = s [=] [=] [= p= ss o |& [3 ~ -~ - 2 0 00 0 [=]
S eS o [2 = [=] [=3 o r= = = a ~~ < SE — o [= =} = ! c 3 ~ = = TT Tw T 2 - . - 15 eg o o <> oo coo © ~ ~ ~ £ ’4 -~ ° ~ ~~ ae =~ r > -— §7 |dodadadddddd dag gs [5 g. = |ggggsgSssssSS 2 Tg ToT gk
SY Sogdoooossas0850s522s5S 58]
AZ FARRAR ANNANRNANZANRZASZNSYSHE
3 . a p=
Z g
Z boy 2 =
Q £
[3] uot x ~ ° a |= = 3 z |e ©] = TaN aN Zz = od . OO oI ITI Ls
ZT ££ LF 1zZzzz = |E
Z2Q H_SL23533535 Q IT
Sa sa Lfoz=== = |e 55 S2923108080 T |8 zr 99 Q@IGSEELIISS a Z |& ~ L La 2025 Wo WD ~ S = 00 Ow SH LOT >>> TZ £ o " [} ! ) p22 2 TEN IESE A220 ZZ 9 |= { Lm T2000 > T = ETN (@) - > a 28S 2I LiFe 20 EER YF TF |< 62207 2ERZF 00 FEF 2 => > I=)
Laxalt TL 2 352 w SL i |e
Soo SH 23> E05 = = |g
SQP>QE87 38510037 20 © |S
EE -NE TR AE Snir SCN + EUR oO ! ra) >EB E22 LIE L3R2F 586555 Yr £2 = |=
ORE9R33IE0EQ see ER EF £2252 V YESS Sv 8 b= = 5 = So
IG) [TI = —
EOREQRSJSTES3929%T LT 25 © (8 35828 sas 5=8<c22=2= OL &L [©
BANC L2<R3LeLsI299 3 4 |s
LS bib LLB SE 282565 Je & |§
SHUN dN Pag FLT HY wv wn UR 2
ZN 7 I Lo res ZL 0 ow © 19
FS YUSHdR ET LESS CNS Be oo |S
NIT LLLTEELEC S57 oF 0 ae 2 <3 £22880, 4c QEREET Sc T8 3 [8 <1iSiELsEReR rz: 35 3 |8
SEE E8785 0<c2332 80 — i -
BERR BRE tal? EE EE [Z] TAAT OPW ETE ET SO LL = s 2 — EC BA I Ne I lol ol - © [4 2 lo FODEE 3 2ESZ eve REE £2 £ |[O ! = ‘no = " =
A I GT TSS CESS RE®P2222 KL LE = [7 Sec fn Emad Esdsac an LQ 2 — Q Ena PATNA CEZTT cL sy 52 a | ¥ = |= rr I mESSTL8 AS55858 8 = ) 0 88 8B 222208 nNnY ip 2 Z 3 RAPALEE HOF TTS dogo Ss oo [8 on ae} OOOO [14] Q Og £020 8D A go al pe 1 owen EE S53 Re] < < — 5) tb PIECES EE Nn BREE JE =O vB «CL Zz -_ z | 5 SSCL TRLLTRIBRL L588 So oo |E & a IIITI<OA<0RLEIT<LTIT << << |=
Claims (20)
1. A modified peptide derived fram H-Arg-Ser-Phe-Thr-Leu-Ala-Ser-Ser- Glu-Thr-Gly-Val-Gly-OH (formula I) having general formula Q- A1-A2- A3-A4-AS-A6-AT-AB-A9-A10-A11-A12-A13- Z (formula IT) wherein Al through A13 correspond with the amino acids of formula I, Q corresponds with H and Z corresponds with OH characterized in that 1 to 6 modifications are selected from one or more of the groups a, b or ¢ consisting of a) substitution of 1-6, preferably 1-4 amino acids at A1 through A13 with non-natural amino acids or f amino acids b) substitution of one or more amide bonds with reduced amide bonds or ethylene isosteres c) substitution at Q and/or Z wherein Q is H, (Ci¢)alkyl, formyl, (C,.s)alkylcarbonyl, carboxy(Ci.¢)alkyl, (Ci. s)alkyloxycarbonyl, (C;)alkenyloxycarbonyl, (Ce-14)aryl(Ci.6)alkyl; (Ce. 1aryl(Ci.)alkyloxycarbonyl, CHs(OCH;CH;),-OCH,-C(O)- wherein n is 1-10, HOCH;«(CHOH),,-CH>~ wherein m is 3-4; 1-methyl-pyridinium-3- carbonyl, 1-methyl-pyridinium-4-carbonyl or Lys, or Q is absent if Al is HzN-C(=NH)NH-(CH,),~-C(O)-wherein n is 2-5; Al is L-Arg, D-Arg, L-Lys, D-Lys, L-Ala, D-Ala, H;N-C(=NH)NH- (CH2),-C(O)-wherein n is 2-5, HoN<CH,),-C(O)-, wherein n is 2-7, (R)- {-NH-CH[(CHz),-NH-C(=NH)-NH,]-CH,-C(O)- }, wherein n is 2-5 or (5)-{-NH-CH[(CH:),-NH-C(=NH)-NH,]-CH,~C(0)-}, wherein n is 2-5 or -N[(CH.),-NH-C(=NH)-NH,]CH,C(O)-, wherein n is 2-5; A2 is L-Ser, D-Ser, L-hSer, D-hSer, L-Thr, D-Thr, L-Ala, D-Ala, Gly or - N[(CH),-OH]-CH,-C(0)- wherein n is 2-5; A3 is L-Phe, D-Phe, L-Phe(X), D-Phe(X) wherein X is independently selected from one or more of (C;)alkyl, hydroxy, halo, (C;. ¢)alkylcarbonylamino, amino or nitro, L-Hfe, D-Hfe, L-Thi, D-Thi, L- Cha, D-Cha, L-Pal(3), D-Pal(3), L-1-Nal, D-1-Nal, L-2-Nal, D-2-Nal, L- Sex(Bzl), D-Ser(Bzl), (R)-{-NH-CH(CHj-aryl)-CH.-} or (§)-{-NH- CH(CH:-aryl)-CH;-} or (R)-{-NH-CH(CH.-aryl)-CH>-} or (§)-{-NH- AMENDED SHEET oo PCT/EP00/10230 CH(CHy-aryl}-CHxr }; A4 is L-Thr, D-Thr- L-Ser-, D-Ser, L-hSer, D-hSer, L-Alz, D-Ala or Gly; - AS is L-Leun, D-Ley, L-lle, D-II, L-Val, D-Val-, L-Nva, D-Nva, L-Ala, D-Ala, Gly, (R)-{-NH-CH(CH;-CH(CHj)2)-CHz-}, or (5)-{-NH-CH(CHr- CH(CH:)::}-CHy- }; Ab is L-Ala, D-Ala or Gly; A7 is L-Ser, D-Ser, L-bSer, D-hSer, L-Thr, D-Thr, L-Ala, D-Ala or Gly; ASB is L-Ser, D-Ser, L-hSer, D-bSer, L-Thr, D-Thr, L-Ala, D-Ala or Gly; A9 is L-Glu, D-Glu, L-Asp, D-Asp, L-Ala, D-Ala or Gly; A10 is L-Thr, D-Thr, L-Ser, D-Ser, L-hSer, D-hSer, L-Ala, D-Ala or Gly; a. Allis Gly, L-Als, D-Ala or -NH-CH,-CH,~; A12 is L-Val, D-Val, L-Nva, D-Nva, L-Lew, D-Lew, L-lle, D-Tle, (R)-{- NH-CH[CH(CH3),}-CHz-}, (S)-{-NH-CH[CH(CB3)]-CB>-}, (R)-{-NH- CH[CH;CH:CH3]-CHz-}, (§)-{-NH-CH[CH,CH>CH3]-CH>-}, (R)-{-NH- CH{CH,CH(CHs),]-CHz-}, (5)-{-NH-CH[CH,CB(CH3):}-CH>-}, RR)-{- NH-CH[CH>(CH(CH;)-CH,CH3]-CH>-}, (RS)-{-NH-CH[CH(CH(CHa} CH:CHs]-CHa-}, (SR)-{-NH-CH[CHx(CH(CHs)-CH.CH;}-CHa-, or (55) {-NH-CH[CHy(CH(CH)-CH,CH;}-CH;-}; A13 is Gly, L-Ala or D-Ala and Z is OR wherein R is H, (Cy.g)alkyl, (Co)alkenyl (Ce1o)aryl(Cr-a)alkyl, (Cas-13)heteroaryl(C; ¢)alkyl or NR;R> wherein R; and R; are independently selected from H, (Cy.¢)alkyl or (Ce-14)aryl(Ci)alkyl and wherein optionally the peptides may be extended at the N and C terminal end next to Al and Al3 with up to 10 amino acids.
2. The peptide according to claim 1 wherein Q is H, (Ci)alkyl, (Ci¢)alkylcarbonyl, carboxy(Ci)alkyl, (Ci¢)alkyl- oxycarbonyl, CH3(OCH,CHj)s-OCH;-C(O)- wherein n is 1-10, HOCH,- (CHOH)x-CHy- wherein m is 3-4; 1-methyl-pyridinium-3-carbonyl, 1- methyl-pyridinium~4-carbonyl or Lys, or Q is absent if Al is HoN- C(=NH)NH+(CHa)s-C(O)-wherein n is 2-5; Al is L-Arg, D-Arg, L-Ala, HoN-C(=NH)NH~(CH.).-C(O)-wherein n is 2-5, HoN-(CH2)n-C(0)-, wherein nis 2-7, (5)-{-NH-CH[(CH2).-NH- C(=NH)-NH;]-CH2>~C(0)-}, wherein n is 2-5 or -N[(CHa),-NH-C(=NH)- NH;)CH2C(O)-, wherein n is 2-5; A2 is L-Ser, L-Ala, D-Ala, Gly or -N[(CH2).-OH]-CH>-C(0)- wherein n AMENDED SHEET
Co PCT/EP00/10230 a 38 1s 2-5; i A3 is L-Phe, D-Phe, L-Phe(X) or D-Phe(X) wherein X is halo or nitro, L- Hie, L-Thi, L-Cha, L-Pal(3), L-1-Nal, L-2-Nal, L-Ser(Bzl) or (5)-{-NH- CH(CHz-aryl)-CHz-}; Adis L-Thr or L-Ala; AS is L-Leu, L-Ala, or (S)<{-NH-CH(CH~CH(CH,),)-CH>-}; A6 is L-Ala or Gly; A7is L-SerorL-Ala; ~ A8isL-Seror L-Alg; A9is L-Glu or L-Als; a Al01is L-Thr or L-Als; All is Gly, L-Ala or -NH-CH,-CH-; A12 is L-Val or (§)-{-NH-CH[CH(CH3),]-CH>-}; Al3 is Gly or L-Ala and Z is OR wherein R is H or NR R; wherein R; and R; are independently selected from H or (Cy.4)alkyl.
3. The peptide according to claims 1-2 wherein Q is H, methyl; acetyl; carboxymethylene, methoxycarbonyl; CH3(OCH,CH2);-OCH,-C(0)-, D-1-glucityl, 1-methyl-pyridinium-3- carbony! or 1-methyl-pyridinium-4-carbonyl, or Q is absent if Al is HoN- C(=NH)NH~(CH,);-C(0)-; Al is L-Arg, D-Arg, L-Ala, HyN-C(=NH)NH~CH,);-C(O)-, HoN-(CHa),- C(0)-, wherein n is 5-7, (S)-{-NH-CH[(CH3);-NH-C(=NH)-NH,]-CHa- C(O) } or -N[(CH2);-NH-C(=NH)-NH;]CH,C(0)-; A2 is L-Ser, L-Ala or -N[(CHy),-OH]-CH,-C(0)-; : A3 is L-Phe, D-Phe, L-Phe(X) wherein X is halo or nitro, L-Hfe, L-Thi, L-Cha, L-Pal(3), L-1-Nal, L-2-Nal or L-Ser(Bzl) and Z is OH, NH, or NHEt.
4. The peptide according to claims 1-3 wherein the general formula is Q-A1- A2-A3-Thr-Leu-Ala-Ser-Ser-Glu-Thr-A11-A12-Gly-Z (formula III)
5. The peptide according to claims 1-4 having 1-4 modifications.
6. The peptide according claim 5 having 2-3 modifications.
7. The peptide according to claim 4 wherein Al is L-Arg, D-Arg, H;N-C(=NH)NH-(CH3)s-C(0)-, H;N-(CH.),-C(0)-, wherein n is 5-7 or -N[(CH,)z-NH-C(=NH)-NH:]CH,C(0)-, AMENDED SHEET
Co PCT/EP00/10230 a 39 A2 is L-Ser or -N[(CH;),-OH]-CH;-C(0)-, A3 is L-Phe, L-Phe(X) wherein X is halo, L-1-Nal, L-2-Nal, L-Ser(Bzl), L-Thi, L-Cha or L-Pal(3).
8. The peptide according to claims 6 or 7 wherein the general formula is Q- Arg-A2-Phe-Thr-Leu- Ala-Ser-Ser-Glu-Thr-Gly-A12-Gly-Z (formula IV).
9. A peptide selected from the group comprising desaminoargininyl-Ser- Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-NHo, desaminoargininyl- Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-OH, CHa- (OCHaCH,)3-OCH,-C(O)-Arg-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr- Gly-Val-Gly-NH,, D-1-glucityl-Arg-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu- Thr-Gly-Val-Gly-OH, CH30-C(O)-Arg-Ser-Phe-Thr-Leu-Ala-Ser-Ser- Glu-Thr-Gly-Val-Gly-OH, Ac-Arg-Ser-Phe-y-[CH.NH]-Thr-Leu-Ala- Ser-Ser-Glu-Thr-Gly-Val-Gly-NH,, Ac-Arg-Ser-Phe-Thr-Leu-y- [CHoNH]-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-NH;, Ac-Arg-Ser-Phe-Thr- Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-y-[CH;NH]-Gly-NH,, Ac-Arg- N[(CHz)2~OH]-CHa-C(O)-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val- Gly- NHa, Ac-Arg-N[(CH,),-OH]-CH;-C(O)-Phe-Thr-Leu-Ala-Ser-Ser- Glu-Thr-Gly-Val-y-[CH;NH]}-Gly- NH,, H-Arg-Ser-Phe(Cl)-Thr-Len- Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-OH, HoN-(CHy)s-C(O)-Ser-Phe-Thr- Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-OH, H;N-(CH,)e-C(O)-Ser-Phe- Thr-Leu-Ala-Ser-Ser-Glu- Thr-Gly-Val-Gly-OH, (N-methyl-nicotinoyl)*- _ Arg-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-OH. AMENDED SHEET
40 PCT/EP00/10230
10. A peptide according to any of the claims 1-9 for use as a therapeutical substance.
11. Pharmaceutical composition comprising one or more of the peptides according to claims 1-9, and a pharmaceutically acceptable carrier.
12. Use of one or more of the peptides according to claims 1-9 for the manufacture of a pharmaceutical preparation for the induction of specific T-cell tolerance to an autoantigen in patients suffering from autoimmune disorders, more specifically arthritis.
13. Diagnostic composition comprising one or more of the peptides according to any of the claims 1-9 and a detection agent.
14. A substance or composition for use in a method for the induction of specific T-cell tolerance to an autoantigen in patients suffering from autoimmune disorders, more specifically arthritis, said substance or composition comprising one or more of the peptides according to claims 1-9, and said method comprising administering said substance or composition.
15. A peptide according to claim 1, substantially as herein described and illustrated.
16. A composition according to claim 11, substantially as herein described and illustrated.
17. Use according to claim 12, substantially as herein described and illustrated.
18. A composition according to claim 13, substantially as herein described and iltustrated.
19. A substance or composition for use in a method of treatment according to claim 14, substantially as herein described and illustrated.
20. A new peptide, a new composition, a new use of a peptide according to any of claims 1 to 9, a new diagnostic composition, or a substance or composition for a new use in a method of treatment, substantially as herein described. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99203427 | 1999-10-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200202577B true ZA200202577B (en) | 2003-09-23 |
Family
ID=8240756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200202577A ZA200202577B (en) | 1999-10-18 | 2002-04-02 | Modified peptides and peptidomimetics for use in immonotherapy. |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP1226167A1 (en) |
JP (1) | JP2003512388A (en) |
KR (1) | KR20020047245A (en) |
CN (1) | CN1379786A (en) |
AR (1) | AR026068A1 (en) |
AU (1) | AU780238B2 (en) |
BR (1) | BR0014803A (en) |
CA (1) | CA2386398A1 (en) |
CO (1) | CO5271650A1 (en) |
CZ (1) | CZ20021356A3 (en) |
HK (1) | HK1046693A1 (en) |
HU (1) | HUP0203504A3 (en) |
IL (1) | IL148778A0 (en) |
MX (1) | MXPA02003520A (en) |
NO (1) | NO20021763D0 (en) |
NZ (1) | NZ518256A (en) |
PE (1) | PE20010692A1 (en) |
PL (1) | PL354590A1 (en) |
RU (1) | RU2002113107A (en) |
SK (1) | SK6842002A3 (en) |
TR (1) | TR200201036T2 (en) |
WO (1) | WO2001029081A1 (en) |
ZA (1) | ZA200202577B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002951212A0 (en) * | 2002-09-04 | 2002-09-19 | Monash University | A method of modulating cellular activity and molecules for use therein |
WO2007117665A2 (en) * | 2006-04-06 | 2007-10-18 | Purdue Research Foundation | Derivatization-enhanced analysis of amino acids and peptides |
EP2114462B1 (en) * | 2006-12-21 | 2013-06-05 | Universite De Geneve | Compounds for fluorescence imaging |
CA2740028A1 (en) | 2008-01-23 | 2009-07-30 | Herlev Hospital | Ykl-40 as a general marker for non-specific disease |
US8580520B2 (en) | 2008-09-15 | 2013-11-12 | Herlev Hospital | YKL-40 as a marker for gastrointestinal cancers |
US11014970B2 (en) * | 2014-11-07 | 2021-05-25 | Kineta Chronic Pain, Llc | Modifications and uses of conotoxin peptides |
EP3466963A1 (en) * | 2017-10-05 | 2019-04-10 | Suigeneris Farmacosmetics, S.L. | Anticancer peptides and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL115744A (en) * | 1994-10-27 | 2000-07-16 | Akzo Nobel Nv | Peptides comprising a subsequence of human cartilage glycoprotein - 39 |
IL120561A0 (en) * | 1996-04-24 | 1997-07-13 | Akzo Nobel Nv | Peptides suitable for use in immunosuppressive therapy |
CA2252417A1 (en) * | 1996-06-07 | 1997-12-11 | Zeneca Limited | Peptide derivatives |
IL122233A (en) * | 1996-12-06 | 2001-04-30 | Akzo Nobel Nv | Method of preparing cell surface monolonal antibodies and pharmaceutical compositions and diagnostic reagents containing them |
-
2000
- 2000-10-12 CA CA002386398A patent/CA2386398A1/en not_active Abandoned
- 2000-10-12 TR TR2002/01036T patent/TR200201036T2/en unknown
- 2000-10-12 CN CN00814418A patent/CN1379786A/en active Pending
- 2000-10-12 IL IL14877800A patent/IL148778A0/en unknown
- 2000-10-12 SK SK684-2002A patent/SK6842002A3/en not_active Application Discontinuation
- 2000-10-12 EP EP00972790A patent/EP1226167A1/en not_active Withdrawn
- 2000-10-12 AU AU11396/01A patent/AU780238B2/en not_active Ceased
- 2000-10-12 RU RU2002113107/15A patent/RU2002113107A/en not_active Application Discontinuation
- 2000-10-12 WO PCT/EP2000/010230 patent/WO2001029081A1/en not_active Application Discontinuation
- 2000-10-12 BR BR0014803-2A patent/BR0014803A/en not_active IP Right Cessation
- 2000-10-12 NZ NZ518256A patent/NZ518256A/en unknown
- 2000-10-12 JP JP2001531879A patent/JP2003512388A/en not_active Withdrawn
- 2000-10-12 MX MXPA02003520A patent/MXPA02003520A/en unknown
- 2000-10-12 PL PL00354590A patent/PL354590A1/en not_active Application Discontinuation
- 2000-10-12 CZ CZ20021356A patent/CZ20021356A3/en unknown
- 2000-10-12 HU HU0203504A patent/HUP0203504A3/en unknown
- 2000-10-12 KR KR1020027004940A patent/KR20020047245A/en not_active Application Discontinuation
- 2000-10-17 PE PE2000001107A patent/PE20010692A1/en not_active Application Discontinuation
- 2000-10-18 CO CO00079334A patent/CO5271650A1/en not_active Application Discontinuation
- 2000-10-18 AR ARP000105458A patent/AR026068A1/en unknown
-
2002
- 2002-04-02 ZA ZA200202577A patent/ZA200202577B/en unknown
- 2002-04-15 NO NO20021763A patent/NO20021763D0/en not_active Application Discontinuation
- 2002-11-13 HK HK02108208.9A patent/HK1046693A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL148778A0 (en) | 2002-09-12 |
MXPA02003520A (en) | 2002-08-20 |
AR026068A1 (en) | 2002-12-26 |
HK1046693A1 (en) | 2003-01-24 |
NZ518256A (en) | 2004-01-30 |
AU1139601A (en) | 2001-04-30 |
WO2001029081A1 (en) | 2001-04-26 |
TR200201036T2 (en) | 2002-08-21 |
PL354590A1 (en) | 2004-01-26 |
JP2003512388A (en) | 2003-04-02 |
CZ20021356A3 (en) | 2002-07-17 |
HUP0203504A3 (en) | 2005-03-29 |
RU2002113107A (en) | 2004-01-10 |
NO20021763L (en) | 2002-04-15 |
NO20021763D0 (en) | 2002-04-15 |
HUP0203504A2 (en) | 2003-04-28 |
CN1379786A (en) | 2002-11-13 |
PE20010692A1 (en) | 2001-07-06 |
AU780238B2 (en) | 2005-03-10 |
CO5271650A1 (en) | 2003-04-30 |
CA2386398A1 (en) | 2001-04-26 |
EP1226167A1 (en) | 2002-07-31 |
KR20020047245A (en) | 2002-06-21 |
BR0014803A (en) | 2002-06-11 |
SK6842002A3 (en) | 2002-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6509033B1 (en) | Immunomodulatory peptides | |
US20060093615A1 (en) | Tumor antigen based on products of the tumor suppressor gent WT1 | |
CA2415938A1 (en) | Alpha-msh related compounds and methods of use | |
AU2001275930A1 (en) | Alpha-msh related compounds and methods of use | |
AU703120B2 (en) | Composition and methods for enhancing immune responses mediated by antigen-presenting cells | |
WO1996012737A9 (en) | Compositions and treatment for multiple sclerosis | |
WO1996012737A2 (en) | Compositions and treatment for multiple sclerosis | |
JPH09507861A (en) | Novel peptides derived from self-antigens for use in immunotherapy of autoimmune diseases | |
JP3468528B2 (en) | Peptide derivative | |
US7122193B1 (en) | Retro peptides, antibodies thereto and their uses for vaccination and in vitro diagnosis | |
AU780238B2 (en) | Modified peptides and peptidomimetics for use in immunotherapy | |
JP2001504836A (en) | Peptide derivative | |
AU718436B2 (en) | Synthetic peptides and pharmaceutical compositions comprising them | |
AU758310B2 (en) | Novel peptides for use in immunotherapy of autoimmune diseases | |
US6423315B1 (en) | Synthetic peptide for treatment of autoimmune arthritis | |
JP2001511143A (en) | Peptides containing T cell epitopes specific for collagen II | |
Boyer et al. | Contribution of antigen processing to the recognition of a synthetic peptide antigen by specific T cell hybridomas | |
Skarlas et al. | HLA‐DQ7 β1 and β2 derived peptides as immunomodulators | |
MXPA02009698A (en) | Identification of potential immunodominant acetylcholine receptor alpha subunit peptides. | |
Paz | Antigenic peptides presented by MHC-I undergo intermediate processing steps in the cytosol and the endoplasmic reticulum |